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Abstract
Mechanisms of Resistance against B Cell Targeting Treatments for Myasthenia Gravis
Ruoyi (Roy) Jiang
2021

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by
autoantibodies that disrupt neuromuscular transmission by targeting components of
neuromuscular junctions, such as the acetylcholine receptor (AChR, 90% of patients) and
muscle specific kinase (MuSK, 10% of patients). Treatments that address the underlying
causes of MG target the cells responsible for producing these autoantibodies. Two such
treatment strategies are predominantly used: (1) surgical resection of the thymus (a
reservoir for auto-antigen specific B cells in patients with AChR MG) and (2) systemic
therapy targeting subsets of autoantibody-producing B cells. The thymus is a known
anatomic reservoir for B cells that can produce pathogenic AChR autoantibodies, and
resection of the thymus has long been known to improve MG symptoms. However, many
patients also fail to achieve complete remission after thymectomy. Rituximab (RTX) is a
B cell depleting agent used in the management of an increasingly wide range of
autoimmune diseases. Many AChR and MuSK MG patients achieve remission after RTX
but relapse following treatment cessation can occur for some patients. In both cases, I
was interested in testing the possibility that the failed depletion of B cells relevant to
disease may drive poor responses.

In my thesis research, I sought to investigate the characteristics of B cells that escape
depletion and contribute to disease in patients with MG. To accomplish, I set out to
complete three related aims: (1) test whether B cell clones that persist include those that
are specific for the autoantigen (in MuSK MG), (2) test whether persistent B cell clones
are related to a tissue source (in AChR MG), and (3) quantify how the amount of B cell
persistence relates to disease status (AChR MG). I first show that B cells specific for the
MuSK autoantigen in patients who relapse after treatment with RTX emerge from the
failed depletion of B cell clones that existed prior to depletion therapy. I characterized
these clones using a method I developed called single cell tracing of adaptive immune
repertoires (STAIR) that allows for the unbiased identification and transcriptional
characterization of B cells (including those that are autoantigen-specific) that escape
RTX depletion by combining high-depth bulk repertoire sequencing methods with single
cell gene expression and repertoire analysis. I also showed that thymus-derived B cell
clones persist in the circulation after thymectomy. The frequency of these clones in the
circulation after thymectomy correlated with poor responses to thymectomy and have
distinct characteristics. Finally, I showed that the persistence of B cell clones after B cell
depletion correlated with outcomes measured in a clinical trial studying the use of RTX
for the treatment of AChR MG. These results demonstrate that the failed depletion of
relevant B cell subsets may drive poor therapy responses in MG and offer a deeper
understanding of the underlying immuno-pathophysiology. The results from these studies
suggest that the optimization of systemic immunotherapy to target B cells that escape
depletion could lead to definitive treatments for MG.
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Chapter 1: Introduction
Significance
Myasthenia gravis (MG) is an autoimmune disorder that is diagnosed at an incidence of
approximately 5 per 1,000,000 person-years (1). The symptoms of MG arise from
pathogenic autoantibodies specific for components of the neuromuscular junction
responsible for generating action potentials such as the nicotinic acetylcholine receptor
(AChR) in 90% of patients, or muscle-specific kinase (MuSK), a protein responsible for
AChR channel clustering, in 10% of patients (2). The disease prevalence of MG has
increased over time owing to improved outcomes and increased longevity; more patients
now live with chronic MG than ever before (3). In addition, MG crises occur in
approximately 20% of patients at some point in their disease course resulting in urgent
treatment and costly hospitalization (3).

Current disease-modifying treatments for MG aim to deplete B cells that make
autoantibodies against AChR and MuSK but the possibility remains that some B cells
may escape. Thus, the main goal of the work described in this dissertation is to identify
and characterize reservoirs of B cells that escape removal in patients with MG, a
necessary step in the optimization of MG therapy.

Rituximab for the treatment of myasthenia gravis
Our clinical collaborators recently demonstrated that the anti-CD20 B cell depleting
agent rituximab (RTX) was effective for treating AChR and MuSK MG (4, 5). For
instance, in one study involving six patients, reductions in anti-AChR antibody titers and

3

clinical improvement were observed for all subjects (5). An independent group also
found that AChR and MuSK MG patients undergoing therapy with RTX benefited from
treatment (6, 7). Indeed, these studies demonstrate that the rate of complete stable
remission (CSR, reflecting symptoms and use of treatments for symptoms) for the use of
RTX in MuSK MG could reach 100%.

However, our group also observed that some participants, particularly those with AChR
MG, did not benefit from treatment, and relapses occurred on follow-up. For 56% of
patients, an average of 36 months elapsed before relapse, similar to the 54% observed in
another study (6, 8). Patients with MuSK MG also experienced relapses including some
who technically achieved an MGFA-PIS (post-intervention status) of CSR (9). In these
subjects, plasmablast expansions were identified with BCRs specific for autoantigen
(when expressed as recombinant monoclonal antibodies) (9).

Poor RTX responses are widely speculated to arise due to the incomplete depletion of B
cell subsets. The heterogeneous depletion of B cell subsets by RTX is widely known; for
instance, plasma cells are depleted poorly owing to low levels of surface CD20 (10–12).
Relapses after RTX depletion have also been observed in the context of rheumatoid
arthritis (RA), lupus (SLE) and autoimmune vasculitides (13, 14). In RA and SLE, RTX
associated relapses are correlated with elevated frequencies of memory B cells; the
incomplete depletion of antigen-experienced B cell subsets may therefore be an important
factor in poor responses to RTX (15–18).
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Disease-causing B cells can be found in the thymus
The thymus is a reservoir for B cells that can secrete AChR autoantibodies (19, 20). In a
large fraction of patients with AChR MG (70%), thymic abnormalities may be identified.
While the thymus is involuted after puberty, in patients with AChR MG, hyperplastic
changes may be observed, sometimes accompanied by the presence of visible germinal
centers (21, 22).

Explantation experiments of human MG thymus in immunodeficient mice have
demonstrated that thymus B cells are sufficient for disease-causing AChR autoantibody
production (23). Staining with radio-labelled AChR can detect B cells specific for AChR
in human thymus (24). Finally, B cells from the thymus, particularly those with markers
for plasma cells, have been shown to be capable of secreting AChR autoantibodies in
vitro (19, 25). Empiric clinical findings have supported the use of thymectomy as a
therapeutic approach for treating a AChR MG (26). Thymectomy for non-thymomatous
AChR MG was recently demonstrated to be more effective that treatment with steroids
alone in a multi-center randomized clinical trial (RCT )called MGTX (22, 27, 28). The
RCT demonstrated that patients who underwent thymectomy experienced a significant
improvement in their MG symptom scores, decrease steroid use and decreased
hospitalization over 3 years. This trial offered rigorous demonstration that eliminating
the thymus, a reservoir of disease-causing B cells, could be used to treat AChR MG.

While the MGTX trial met its primary endpoint, not all subjects consistently improved
after thymectomy; some patients continued to improve after removal while others
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plateaued. This could reflect the persistence of B cells specific for AChR. Other studies
have also highlighted incomplete depletion of B cell reservoirs after thymectomy (29–
32). It is known that a large fraction of patients (40-50%) achieve stable remission but
only decades after thymectomy (33, 34). Thymectomy is known to reduce AChR
autoantibody titers (35) however other studies show that these levels rarely fall to
undetectable levels and can persist long after the procedure (32). While the thymus is
among the main sources of anti-AChR antibody-producing ASCs, bone marrow and
lymph node niches have also been identified that contain B cells capable of secreting
anti-AChR antibodies (29–31). Other studies have shown that repeat thymectomy may be
beneficial even when there is no evidence of residual thymus on imaging (computed
tomography) after the procedure (36, 37).

Value of studying both RTX and thymectomy
Understanding why heterogeneous responses to both RTX and thymectomy occur is
therefore critical to improving the management of MG. Thymus B cells may be
incompletely removed in patients who fail to benefit from thymectomy, and B cell clones
that fail to be depleted by RTX may be thymus derived. Previous thymectomy status is an
important factor in trials on the use of RTX in MG (5) (which may reflect the importance
of pathogenic B cell tissue localization in contributing to disease resistance) and tissueresident B cells are known to escape RTX depletion (38).

Moreover, optimizing systemic immunotherapy could benefit both patients treated with
thymectomy and RTX who fail to benefit adequately after therapy. My dissertation
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research aims to characterize these B cells and test the hypothesis that disease-causing,
antibody-secreting B cell subsets escape depletion including those that may be tissue
derived. B cell persistence would therefore be predicted to correlate with treatment
outcomes.

Repertoire Sequencing
The technique I used to identify B cells that escape depletion in my dissertation research
is generally referred to as adaptive immune receptor repertoire sequencing (AIRR-Seq).
AIRR-Seq uses next-generation sequencing (NGS) techniques to sequence the variable
regions of B cell and T cell receptors. Until recently, NGS approaches for generating
immune repertoires commonly began with genomic DNA or mRNA, and therefore
generate high-depth bulk repertoires of unpaired immunoglobulin or T cell receptor
V(D)J sequences (39–41). More recent approaches use “high-throughput” single-cell
techniques to construct repertoires—sometimes with paired gene expression (42–45).
Nevertheless, prior to this dissertation research, no study had yet investigated the
circulating B cell repertoire using high-throughput single cell repertoire sequencing
paired with gene expression with autoimmune disease.

While the research presented in this dissertation is therefore highly novel, several studies
had already previously explored some of the topics eventually elucidated by this work.
That is, studies published immediately before and during the course of this dissertation
confirm some of the findings that will be presented here. For instance, these studies
identified persistent expanded clones and associations between clonality and responder
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status (46–48). A recent study using bulk AIRR-Seq to investigate the use of RTX for
treating ANCA-associated vasculitis (AAV) demonstrated that persistent clonotypes are
isotype-switched, which I also observed in my work (48). These studies establish the
generalizability of the work presented here.

Innovation
In the research presented in this dissertation, we also combined bulk as well as single cell
AIRR-Seq approaches to leverage depth and single-cell resolution. This technique
described earlier as STAIR allows for unbiased transcriptional characterization of
persistent B cells and represents a novel way of studying the repertoire. In comparison to
the examination of overlap between bulk BCR repertoires alone, this approach also
allows for the characterization of the expression profile of persistent, disease-relevant B
cells (including those specific for antigen) at single-cell resolution. Moreover, this
approach allows for the identification of genes representing novel therapeutic targets and
is unbiased in that it is not limited to the set of known B cell surface markers used for
characterizing B cell subsets. Rather than relying on a limited set of flow cytometry
markers, hundreds of markers are used that allow for the accurate identification of B cell
subsets.

Thus, the findings from this dissertation enhance the understanding of B cells in MG by
using novel technologies never applied previously to the study of autoimmune disease.
Moreover, the findings of this research could guide the initiation of new trials targeting
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antigen-experienced B cell subsets in MG, as well as the adoption of new diagnostics for
monitoring depletion in the treatment of autoimmune diseases.
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Introduction:
MuSK is essential for AChR clustering and synaptic differentiation (49). Through
binding MuSK, serum-derived autoantibodies impair clustering of AChRs, and
neuromuscular transmission, thereby causing disease (50). The conspicuous clinical
benefit of BCDT in patients with MuSK MG was recently demonstrated (5, 6, 8).
However, a fraction of patients treated with the anti-CD20 BCDT agent rituximab (RTX)
experienced post-rituximab (post-RTX) relapses despite initial symptomatic responses
and a fall in MuSK autoantibody titer (4, 5, 51, 52). Post-RTX relapse in MuSK MG is
associated with the presence of circulating plasmablast expansions, which include those
that secrete MuSK-specific autoantibodies (9, 53). Previous studies have shown that
antigen-experienced plasma cells or plasmablasts are resistant to BCDT owing to their
low CD20 expression (10, 11, 54, 55). Moreover, memory B cells, which express CD20,
can also be abundant after BCDT, and their increased frequency is associated with postRTX relapses (15, 17). Whether or not plasmablasts, plasma cells or memory B cells
emerge from inadequately depleted circulating B cells (versus emerging entirely de novo)
is not known. The characteristics of antigen-experienced B cells that resist depletion also
remain unclear.

Understanding the mechanisms underlying post-RTX relapse is important for the
development of new modalities for monitoring depletion and more effective therapy
combinations for treating MG and other autoimmune disorders. Accordingly, we sought
to further understand whether post-RTX relapse in MuSK MG is associated with the
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failed depletion of pre-existing B cells, including autoantibody-producing B cell subsets.
In addition, we investigated the phenotype of the B cells that persist throughout the
course treatment and relapse. To this end, we integrated data from multiple profiling
methods on the same patients, including: (1) adaptive immune receptor repertoire
sequencing (AIRR-Seq) to generate high-depth B cell receptor (BCR) libraries from
unselected PBMCs collected at pre-RTX treatment time points and during episodes of
post-RTX relapse; (2) previously published sequences of human monoclonal
autoantibodies, with known specificity for the MuSK autoantigen, that emerged during
post-RTX relapses; and (3) single-cell gene expression analysis with paired BCR
repertoire sequencing, to trace B cell populations temporally and to identify the
phenotype of B cells that emerge during post-RTX relapse. In comparison with the
examination of clonal overlap between bulk BCR repertoires alone, this approach, which
we refer to as Single-cell Tracing of Adaptive Immune Receptor (STAIR) repertoires,
allows for the unbiased characterization of the gene expression profile of persistent,
disease-relevant B cells (including those specific for the autoantigen) at single-cell
resolution. By using this approach, we offer new insights into the mechanism of postRTX relapse in patients with MuSK MG and potential avenues for improving the
treatment of MG and other autoantibody-driven autoimmune diseases.

Results:
Experimental design
We used the following experimental approach (Figure 1A) to identify and characterize B
cell clones that resist RTX depletion in three MuSK MG patients who experienced
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relapses. We first tested whether B cell clones persisted across pre- and post-RTX
repertoires by sequencing the BCR repertoire of unselected PBMCs at high depth using a
bulk approach to capture a large number of sequences for identifying persistent clones.
Second, we tested whether MuSK autoantibody-producing B cells were among these
persistent clones. In previous studies of these same patients, we produced MuSK-specific
recombinant human monoclonal antibodies (9, 53) from single B cells isolated during
post-RTX relapses. Here, though, we sought to determine whether those specific BCR
clones were present in pre-RTX repertoires. Third, we identified the phenotype of both
persistent and non-persistent B cell clones. This was achieved through paired
transcriptional profiling and BCR sequencing of single cells. These BCR sequences were
traced to high-depth bulk sequencing repertoires derived from pre-RTX timepoints. The
transcriptional profiles of persistent and non-persistent B cell clones were then compared.

A subset of B cell clones is refractory to depletion
We first sought to identify clones that escape RTX depletion and contribute to relapses
when the B cell compartment repopulates after treatment. To that end, we sequenced the
B cell repertoire, using our high-depth bulk approach, from three MG patients before and
after treatment (Table S1, S2, Figure 1B). The number of V(D)J sequences isolated for
patient 1 was 639,715; 82,720 from patient 2; and 107,504 from patient 3. Grouping the
sequences into clones—those with a common ancestor based on their V, J gene usage and
junction sequences (56)—generated 187,195; 34,719; and 14,579 clones for patient 1, 2
and 3 respectively (Figure S1). A total of 2,462 clones were found with members that
were present in both the pre-rituximab (pre-RTX) and post-rituximab relapse (post-RTX)
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repertoire (termed persistent clones) in patient 1 (or 1.6% of pre-RTX clones); 902
(4.9%) and 345 (7.6%) were found in patients 2 and 3 respectively (Figure 2A). Given
that clonal relationships are inferred computationally, we next sought to substantiate that
these persistent clones were not the result of sequence similarity that happened by
chance. To estimate the frequency at which clones are spuriously observed to be shared
between the post-RTX and pre-RTX repertoires, the average background sharing between
the post-RTX circulation and the pre-RTX circulation of unrelated individuals was
calculated (e.g post-RTX patient 1 was compared to pre-RTX patient 2). This rate was
used as a null hypothesis to establish the significance of the observed clonal sharing
between post-RTX and pre-RTX repertoires in the same patient. Patient 1 shared an
average of 0.4% clones in comparisons with other patients, patient 2 shared an average of
1.4%, and patient 3 shared an average of 0.9%. Quantification using a clonal overlap
metric demonstrated that the observed overlaps between pre-RTX and post-RTX
repertoires were significantly higher relative to the background (t-test P=0.037) (Figure
2B). These collective data demonstrate that circulating B cell clones persist despite RTXmediated depletion of the repertoire.

Persistent clones are antigen experienced
Next we compared the V(D)J properties of non-persistent clones to persistent clones that
emerge post-RTX to investigate if the latter have distinct characteristics that might
contribute to their persistence (Figure 2C, 2D). Given the possible role of persistent B
cells in recognizing antigen, we characterized features of the repertoire associated with
antigen-experience, namely isotype switching and elevated somatic hypermutation
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(SHM) frequency. High-depth bulk repertoires were first examined to quantify the
difference in isotype frequency among V(D)J sequences from persistent and nonpersistent post-RTX clones. Only B cells displaying an antigen experienced phenotype
were found to be persistent; when the approach shown in Figure 2B was applied to only
B cells displaying a naïve phenotype (unmutated IgM and IgD B cells), no clonal sharing
was observed (one-tailed t-test P=0.317, data not shown). Furthermore, non-persistent
sequences were 43.2% IgM, 6.4% IgD, 24.7% IgG and 25.5% IgA of the repertoire on
average (Figure 2C), and persistent ones were disproportionately switched (15.0% IgM,
2.2% IgD, 27.4% IgG and 55.0% IgA) (ANOVA p=0.027). In addition, the overall SHM
frequency of persistent clones was significantly elevated (Figure 2D) (ANOVA P=0.014),
and this difference in SHM frequency did not depend on the isotype of the sequence
(ANOVA p = 0.287). Therefore, persistent clones are preferentially isotype switched with
elevated SHM, reflecting a more antigen-experienced phenotype.

Persistent clones do not consistently expand or gain SHM
We next sought to determine whether antigen-experience (in terms of clonal expansion
and SHM) was gained by persistent clones during reconstitution of the B cell
compartment after RTX. To that end, the high-depth bulk repertoire was first examined to
test whether persistent clones expand between pre-RTX and post-RTX time points.
Clonal expansion was assessed by computing the change in size of persistent clones
between pre-RTX and post-RTX time points. Average decreases of -11% (95% CI -93%
to +1313%), -85% (95% CI -98% to +439%) and -7% (95% CI -99% to +40.5%) in
clonal size respectively were observed across patients 1, 2 and 3 (one-sample t-test
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P=0.37) (Figure S2A-C). Thus, decreases in clonal size were observed but these
decreases were not significant. Given that persistent clones have elevated frequencies of
SHM, we tested whether individual clones acquire additional SHM by quantifying the
average change in SHM frequency of persistent clones between pre-RTX and post-RTX
time points. The median change in SHM frequency was -0.2% (95% CI -89% to
+1132%), -2.4% (95% CI -74% to 187%) and +4.5% (95% CI -41% to +67%) for
patients 1, 2 and 3 respectively (Figure S2D-F); no consistent change in the SHM
frequency of persistent clones between pre-RTX and post-RTX samples was detected
(one-sample t-test P=0.807). These collective findings suggest that persistent clones are
enriched for features of antigen-experience pre-RTX but do not acquire further antigenexperience between pre-RTX and post-RTX time points.

Some persistent clones are disease relevant and bind MuSK
We then sought to investigate if persistent B cell clones were autoantigen-specific. In two
previous studies, using the same three patients described here, we identified B cell clones
during post-RTX relapse that were specific for autoantigen (Table S3). In the first study,
43 unique B cell clones were used to generate recombinant monoclonal antibodies, all of
which were derived from circulating plasmablasts as this cell type was demonstrated to
produce MuSK-specific antibodies when cultured in vitro (9). In the second, a fluorescent
MuSK antigen bait was used to both identify and isolate MuSK-specific B cell clones
from which an additional 38 recombinant monoclonal antibodies were produced (53). In
total, 11 members of these collective 81 clones bound surface expressed MuSK across a
range of different binding strengths when tested as monoclonal antibodies with a cell-
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based assay (9, 53). The BCR sequences of these clones were compared to the sequences
in high-depth bulk repertoires to identify clonal relatives present both before and after
treatment. Of these 81 clones, 27 were members of clones found in the bulk post-RTX
BCR repertoires. This finding demonstrates that these clones were expanded, since they
were found in unique, independent sample aliquots. We tested if members of these 81
clones were present in pre-RTX repertoires; members belonging to 74 clones were not
observed. However, we observed that seven clones could be found in pre-RTX
repertoires (Figure 3 and Figures S3-5). One of these clones was among the 11 previously
demonstrated to specifically bind MuSK (Figure 3) (9). Thus, disease-relevant and MuSK
autoantigen-specific B cells present during relapse can derive from the failed depletion of
B cell clones that existed prior to therapy.

Antibody-secreting cell-like B cells are more persistent than memory B cells
We next sought to characterize the transcriptional state of persistent B cells to determine
their phenotype in an unbiased manner and quantify how different B cell subsets are
represented among persistent populations. To accomplish this, we carried out single-cell
transcriptome and paired BCR repertoire profiling of circulating post-RTX B cells.
Owing to the high frequency of transitional B cells during post-RTX reconstitution,
IgDlow B cells were selected by sorting prior to single-cell analysis (Figure S6). Further,
the analysis was limited to the switched IgG and IgA repertoire by computationally
filtering out cells with V(D)Js paired with an IgD or IgM constant region. Clones were
identified in the single-cell data sets that were related to clones present in pre-RTX highdepth bulk BCR repertoires. This allowed for direct interrogation of the transcriptomes of
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persistent B cells. That is, we leveraged the resolution offered by high-throughput singlecell transcriptomes and high-depth offered by bulk BCR analysis to perform single-cell
tracing of adaptive immune repertoires (STAIR). From single-cell sequencing, a total of
18,133 cells associated with 14,671 IGH V(D)J sequences were identified (Table S4)
from the same three post-RTX patients and an additional asymptomatic AChR MG
patient used as a control. Gene expression pattern and repertoire characteristics were used
to partition the cells into 11 distinct clusters (Figure S7A-G, Table S5). Clusters of
antibody-secreting cells (ASC), memory B cells, mature naive B cells and transitional B
cells were assigned by analysis of the gene expression of these clusters (Figure 4A).
Because B cells from the single-cell expression analysis could not be experimentally
isolated to assess for antibody secretion or other functional features associated with
plasmablasts/plasma cells, we chose to label the cluster most associated with a
plasmablast/plasma cell signature as antibody-secreting cell (hereafter referred to as
ASC). By combining single-cell repertoires with high-depth bulk pre-RTX BCR
repertoires, a total of 820 persistent clones with members in the single-cell profiling data
were identified. Persistent clones could be identified in both the ASC as well as memory
B cell clusters. The ASC cluster had a higher frequency (27.9%) of persistent clones in
comparison to the memory cluster (14.6%) (Figure 4B, 4C) (t-test P=0.045). As further
confirmation that some ASC and memory B cell clones are persistent, IGH sequences
were also identified from single-cells in the ASC and memory B cell cluster with
identical V(D)J sequences as pre-RTX members (Figure 4B). Thus, these data suggest
that while both ASCs and memory B cells can persist, members of the ASC subset are
more likely to also be found pre-RTX than memory B cells during relapse.
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ASCs have persistence-associated features compared to memory B cells
We next sought to investigate phenotypic characteristics of ASCs compared to memory B
cells during post-RTX relapse to further understand their mechanism of persistence and
identify possible subsets of persistent ASCs. The expression of CD20, the target of
rituximab, was first investigated. To test the association between the expression of CD20
and persistence of ASCs, CD20 expression was examined among B cell subsets. The
ASC cluster was observed to express lower CD20 levels when compared to memory B
cells (t-test P=0.021) (Figure 5A). However, when we examined the expression of CD20
on persistent ASCs compared to non-persistent ASCs, a decrease was observed but this
trend did not reach significance (t-test P=0.15) (Figure 5B).

BAFF (also known as B cell activating factor, B lymphocyte stimulator or BlyS) is a TNF
superfamily member produced almost exclusively by myeloid cells (57, 58). BAFF (and
another TNF superfamily ligand, APRIL) can bind a family of B cell specific receptors to
promote B cell survival. Given that APRIL/BAFF receptor genes have been observed to
play a role in mediating B cell survival after RTX depletion, we investigated the
differential expression of APRIL/BAFF receptor genes (59–61). Persistent ASCs were
not observed to differentially express APRIL/BAFF receptor genes (TACI, BAFF-R and
BCMA) (P=0.085, 0.555, 0.288 for TACI, BAFF-R, BCMA respectively) (Figure 5B).

To investigate other features that might distinguish persistent and non-persistent ASCs,
the relative usage of different isotypes and average SHM frequencies were examined.
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Persistent ASCs were also not observed to differ in terms of isotype usage (ANOVA
P=0.194) or frequency of SHM (ANOVA P=0.101) compared to their non-persistent
counterparts (Figure S8A, B). The clonal diversity (more clonal expansions) of the ASC
cluster was lower compared to memory B cells (t-test P=0.011) (Figure 5C). However,
when we examined clonal diversity within the ASC cluster, a consistent difference
between persistent ASCs compared to non-persistent ASCs was not observed (t-test
P=0.079) (Figure 5D). Finally, the fraction of cells in the ASC cluster was 10.0% of the
total B cell repertoire in the post-RTX cohort (Figure 5E). This was significantly elevated
compared to the 0.5% observed in the control asymptomatic AChR MG sample (onesample t-test P=0.044). However, when we examined if clonal expansion of persistent B
cells between the pre-RTX and post-RTX time points could explain the abundance of
ASC B cells that we observed post-RTX, ASC B cell clones were not consistently found
to expand (or acquire SHM)—between pre-RTX and post-RTX time points
approximately half expanded and the other half shrunk. The average change in clonal size
was therefore not consistent across patients (t-test P=0.099) (Figure S9A-F).

To summarize, persistent ASC cluster members were not observed to differ from nonpersistent members in terms of their expression of CD20 and receptors for BAFF/APRIL,
clonal diversity, isotype usage or SHM frequency. However, ASC cluster members
expressed lower CD20 and were more clonally expanded than memory B cells overall;
these data identify features of the ASC cluster as a whole that may explain their higher
frequency among persistent clones.
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Persistent memory B cell clones are expanded and express low levels of CD20
While ASC clones were observed to be more persistent than memory cells, ASC
members of the MuSK-specific clone identified previously (Figure 3) were also observed
to be related to two members of the memory B cell cluster. Moreover, given the high
frequency of persistent memory B cells observed overall, we next sought to explore if
persistent memory B cells had distinct features compared to non-persistent memory B
cells. We tested CD20 expression, expression of APRIL/BAFF receptors, SHM, isotype
usage and clonal diversity (Figure 6). Persistent memory B cells were observed to have
significantly lower CD20 expression (t-test P=0.022). To investigate whether this
difference in CD20 mRNA would be expected to correlate with surface CD20 expression,
we examined B cells from a published dataset generated using CITE-Seq (62, 63). CD20
surface expression was found to be significantly elevated in cells with higher CD20
mRNA expression across subjects (t-test P= 5.1e-5, Figure S10). Other features of
persistent memory B cells included higher expression of TACI (t-test P=0.037), but lower
expression of BAFF-R (t-test P=0.037) (Figure 6A). Analysis of SHM and isotype usage
revealed that persistent memory B cells also had higher frequencies of SHM across
isotypes (ANOVA P=0.037) (Figure 6B); the fraction of persistent memory B cells
expressing IgG1 (t-test P=0.022) and IgG3 (t-test P=0.025) (ANOVA P= 0.007) was less
than that of their non-persistent counterparts (Figure 6C). We next examined if persistent
memory B cells were clonally expanded compared to their non-persistent counterparts.
They were observed to have lower clonal diversity post-RTX suggesting that they were
clonally expanded (t-test P=0.030) (Figure 6D). Initial clustering of cells based on singlecell gene expression identified six distinct sub-clusters of memory B cells. To better
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characterize the gene expression features of persistent memory B cells, we examined the
most abundant sub-cluster among persistent memory B cells. This cluster (cluster 3)
(Figure 7A and 7B) represented 36.7% of all persistent memory B cells but only 25.0%
of all memory B cells (not the most prevalent overall which was cluster 2) (Figure 7B,
C). Analysis of gene expression showed that cluster 3 was specifically characterized by
lower CD20 expression (t-test P=0.005), higher TACI expression (t-test P=0.008) and
lower BAFF-R expression (t-test P=0.014) compared to other memory B cell sub-clusters
(Figure 7D, S11A). This cluster also displayed a higher frequency of SHM across all
isotypes (ANOVA P=1.46e-6) (Figure S11B) and demonstrated increased usage of IgA
compared to IgG isotypes (ANOVA P=0.0103) (Figure S11C), but was not more clonally
expanded compared to other memory B cells (t-test P=0.169) (Figure S11D).

Unbiased differential gene expression identified 1,282 differentially expressed genes
between memory cluster 3 (enriched for persistent clones) and all other memory B cell
sub-clusters (Figure S12) (FDR < 0.05). The upregulated subset of these genes was
enriched for a MYC signature (or c-Myc, a transcription factor that enhances B cell
survival) and BRCA1/TP53 signature (transcription factors that regulate cell senescence
and cell cycle) (Figure S13, S14) (64–66). The expression of two tissue homing genes
that are the targets of the immunotherapy agents, natalizumab and fingolimod (ITGA4
and S1PR1 respectively), were also observed as upregulated among cluster 3 memory B
cells (P=0.049 for ITGA4 and P=0.039 for S1PR1) (Data File S1) (67). Thus, persistent
memory B cells are clonally expanded and are characterized by a subset of B cells with
elevated SHM, less IgG1 and IgG3 usage, high expression of TACI, low expression of
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CD20 and a gene-expression pattern associated with transcription factors that control cell
survival, proliferation and senescence.

Discussion:
Recent studies have demonstrated the remarkable benefits of RTX-mediated BCDT in
MuSK MG however relapses have been observed in some patients and are associated
with the presence of circulating plasmablasts that express MuSK-specific autoantibodies
(5–7, 9, 53, 68). Through investigating the characteristics of B cells that emerge postRTX, we sought to determine if these disease-relevant B cells derive either from the
failed depletion of pre-existing B cell clones or from de novo generation.

We show that B cell clones, including MuSK-specific autoantibody-secreting B cells,
emerge from the failed depletion of pre-existing clones and that memory B cells serve as
a reservoir for these cells including antigen-specific members (Figure S15). A novel
approach was used that combined multiple methods of sequencing the BCR repertoire
with single-cell gene expression (STAIR) to demonstrate that persistent B cell clones are
comprised of expanded ASCs and memory B cell populations expressing low levels of
CD20 associated with a unique gene-expression profile. Although the persistence of B
cell clones after RTX is not specific to MuSK MG relapse (46, 48, 69), MuSK-specific
ASCs are found during MuSK MG relapse; we show here that these ASCs and their
memory B cell precursors are incompletely depleted by RTX in a subset of MG patients
who experienced post-RTX relapses.
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That many ASCs present after BCDT are related to pre-existing populations is consistent
with a large body of evidence showing that ASCs resist depletion owing to their low
levels of CD20 expression and tissue localization (10, 11, 55, 70); their frequency
predicts poor treatment response in SLE and RA patients (71–74). The finding that
circulating memory B cell clones are also persistent is consistent with data showing that
the frequency of memory B cells also predicts poor responses to RTX in SLE and RA
(15–17). While these previous studies were important for identifying predictors of
outcome, they were not designed to highly resolve B cell subsets due to limitations
inherent with flow cytometry. By comparison, here, the definition of memory using
single-cell transcriptomes does not rely on flow cytometry markers, but rather hundreds
of markers that allow for accurate identification of common gene-expression patterns
associated with memory B cells. Furthermore, by applying STAIR, we were able to
profile persistent memory B cell subsets in detail. A recent study using bulk AIRR-Seq to
investigate the use of RTX for treating AAV (ANCA-associated vasculitis) demonstrated
that persistent clonotypes are isotype-switched, which we also observed in our study (48).
Here, persistence also correlated with a specific gene-expression signature, that is, lower
CD20 expression and differences in APRIL/BAFF receptor expression relative to other
memory B cells.

Studies of RTX responses in anti-MAG-neuropathy (Immunoglobulin M(IgM) Antimyelin associated glycoprotein peripheral neuropathy) and pemphigus vulgaris (PV) (16,
75, 76) demonstrated that poor responses to RTX are associated with increased repertoire
clonality post-RTX. Our results show that persistent memory B cells are more clonally
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expanded than non-persistent memory B cells and suggest that the association between
increased repertoire clonality and poor responses to RTX may result from the persistence
of clonally expanded memory B cells.

Our work is congruent with studies that have shown that BAFF and the differential
expression of receptors for APRIL/BAFF (TACI, BAFF-R, BCMA) on antigenexperienced B cells may lead to poor outcomes after BCDT (59–61, 77). BAFF (also
known as B cell activating factor, B lymphocyte stimulator or BlyS) is a TNF
superfamily member produced almost exclusively by myeloid cells (57, 58). BAFF (and
another TNF superfamily ligand, APRIL) can bind a family of B cell specific receptors to
promote B cell survival. A higher frequency of memory B cells expressing lower BAFFR can be detected in patients with RA relapsing after RTX (61) as well as in patients with
GVHD who respond poorly to RTX (60). This is consistent with our observation that
persistent memory B cells express lower BAFF-R levels. Further, BAFF levels have been
shown to negatively correlate with BAFF-R expression after RTX therapy in primary
Sjogren’s syndrome and SLE (77), and exposure of B cells to soluble BAFF decreases
BAFF-R in vitro. By comparison, exposure to anti-BAFF increases the expression of
BAFF-R on B cells (78). By directly characterizing B cell clones that resist RTX
depletion we are able to show that memory B cell subsets that persist after RTX express
surface markers associated with poor responses to RTX during relapse.

Our analysis showed that ASCs and cluster 3 memory B cells during relapse were
predominantly IgA. We speculate that the abundance of IgA-switched B cells could be
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related to BAFF expression given the known role of BAFF in class switch recombination,
particularly in the gut (79–81). The presence of IgA-switched circulating ASCs has been
shown to depend on BAFF (82). Moreover, IgA secreting plasma cells reduce disease
severity in an experimental autoimmune encephalomyelitis (EAE), owing to their
production of IL-10 (83). Thus, further characterization of how the induction of IgAproducing B cell subsets by RTX occurs, are needed to investigate alternative
mechanisms of BCDT-mediated therapeutic benefit.

The conclusions of this study offer insights into therapeutic and diagnostic avenues for
patients who experience relapses after RTX. Our findings regarding the BAFF/APRIL
system suggest that combining RTX with BAFF pathway inhibitors (e.g. belimumab)
could offer ways to deplete B cells that persist after RTX including autoantibody
producers. Combination strategies involving both belimumab and RTX were successful
in a phase 2a randomized clinical trial in SLE, now followed by an ongoing phase 3 trial
(84, 85). A combination approach using belimumab and RTX has also shown promise for
treating Sjogren’s syndrome (86). This study by no means validates the use of
combination therapy targeting BAFF as standard of care nor do we argue that this is the
only approach to combination therapy; further investigations are warranted to better
understand such strategies. Mechanisms underlying RTX resistance are complex and
may not be limited to B cell persistance. For example, a suggested role for variable
complement activity could alter RTX effectiveness (87). Furthermore, concomitant statin
treatment may introduce conformational changes in the CD20 receptor that impair RTX
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binding or disturb the integrity of RTX-induced translocation of CD20 into lipid rafts,
both of which are important for cytoxicity (88, 89).

We also observed that upregulated genes associated with the subset of memory B cells
most resistant to depletion (cluster 3) included those involved in tissue homing (ITGA4,
S1PR1). S1P receptor is upregulated in lymphocytes localized to lymph nodes and
inflamed tissues and a target of the immunotherapeutic, fingolimod. ITGA4 is a
component of VLA-4, an integrin dimer also responsible for the localization of
leukocytes to inflamed tissue and target of natalizumab (67). We speculate this could
reflect the tissue-associated origin for this subset. This is consistent with evidence
showing that lymph nodes, spleen, bone marrow and tonsils harbor RTX-resistant
memory B cells (17, 18, 38, 90). Therapies such as engineered T cell technology,
including chimeric-antigen receptor (CAR) or chimeric-autoantibody receptor (CAAR) T
cell therapy (91, 92) and other methods for eliminating tissue-localized subsets may be
well suited for preventing and treating relapses.

Existing AIRR-Seq approaches for generating immune repertoires commonly begin with
genomic DNA or mRNA, and produce high-depth bulk repertoires of unpaired
immunoglobulin or T cell receptor V(D)J sequences (39–41). More recent approaches use
single-cell isolation techniques with high-throughput sequencing to construct repertoires,
sometimes with paired gene expression (43–45, 93). The use of these single cell-based
approaches include studies on tumor-infiltrating lymphocytes from cancer biopsies,
infiltrates from the brain of mice and B cells from the spleen of mice after vaccination in
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mice (43–45). No single-cell repertoire studies have investigated the B cell repertoire in
autoimmune disease thusfar. Our ability to extract biologically meaningful results from
STAIR analysis suggests that tracing individual BCR sequences associated with relapse
could provide a powerful tool for monitoring patient responses to immunotherapies that
deplete B and T cells. Moreover, in comparison to techniques that use bulk BCR
repertoire sequencing to monitor therapy progress, this approach allows for the individual
characterization of lymphocytes that resist therapy based on gene expression which may
suggest alternative avenues for treatment (94).

Several limitations of this study should be considered. First, the single-cell gene
expression of B cells was characterized only after RTX depletion. Determining the
phenotype of B cells that resist RTX depletion prior to therapy may be of interest to
identify resistant subsets for targeting prior to relapse. A recent study demonstrated that
not only do B cell clones move between peripheral blood and cerebrospinal fluid over the
course of immunotherapy in some patients with multiple sclerosis (MS), but many have
both memory and plasma cell members (95). Similar studies using single-cell
transcriptomics could identify memory B cell subsets that give rise to autoantibodyproducing plasmablasts during relapse. Second, our results rely on tracing B cell clones
by analyzing their IGH V(D)J sequences alone. While we (and others) have demonstrated
that clonal relationships can be reliably inferred given the diversity of IGH V(D)J
sequences, false positives may occur (56, 96, 97). Third, owing to the abundance of
transitional B cells that re-populate the repertoire during RTX relapse and our interest in
studying antigen-experienced B cell subsets, we excluded IgD+ B cells from our single-
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cell analysis. Nevertheless, a small fraction of B cell receptors paired with an IGHD
constant region (3.2-11.4%) was found in our single-cell data. This is likely because
flow-based sorting is not absolute in eliminating gated populations. Fourth, the expressed
mRNA transcriptome may not always reflect the expression of surface markers used for
sorting. Nevertheless, in the specific case of CD20, we showed a consistent correlation
between CD20 mRNA expression and CD20 surface expression; low expression of
surface CD20 has been associated with resistance to RTX depletion in murine models
(10, 11). Fifth, we were limited to a cohort of three patients owing to the rarity of MuSK
MG relapse after RTX. This limitation was weighed against the benefits of studying a
disease directly caused by antigen-specific antibodies, permitting more definitive
statements about the contribution of persistent antigen-specific B cells to clinical relapse.
Nevertheless, because of the small cohort size, caution should be taken when generalizing
the results of this study to patients with MuSK MG. Finally, although we previously
generated human recombinant MuSK-specific monoclonal antibodies from B cells
present during post-RTX relapse, these monoclonal antibodies recognized MuSK with
different binding capacities ranging from weak to very strong (9, 53). The one we were
successful in tracing to the pre-RTX repertoire in the present study, was among those
showing weaker binding capacity. Accordingly, we can only speculate on its pathogenic
capacity in vivo. That it was a member of a large expanded clone with multiple clonal
variants may suggest that this particular clonal member represented an intermediate step
toward a higher binding disease-causing relative.
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The reported results motivate future investigations. By combining the depth offered by
bulk repertoire sequencing with the resolution of single-cell repertoire and gene
expression, STAIR analysis allows for the characterization of B cells present at multiple
time points in detail. Extending these observations to studies where anti-CD20 therapy
has strong evidence for efficacy, such as MS, may be particularly worthwhile. Applying
STAIR analysis to the simultaneous investigation of other therapies, such as anti-CD19
therapy (inebilizumab)—recently shown to be efficacious for the treatment of NMO—
could allow for the optimal selection of B cell depleting agents for preventing disease
relapse (98). While RTX is a reliable treatment modality for MuSK MG, data for AChR
MG has been mixed and patient relapses do occur (4). An investigation of factors that
contribute to relapse after RTX in the context of AChR MG using similar approaches
could lead to the development of improved therapeutics for diagnosing and treating
patients with MG regardless of disease subtype.

Methods:
Patient-derived specimens
Peripheral blood was collected from MG subjects (Yale Myasthenia Gravis Clinic, New
Haven, Connecticut, USA). A MuSK MG cohort (n = 3) was identified for purposes of
investigation of post-RTX relapses with these characteristics that we have described
previously: (i) a RTX-induced CSR/MM (complete stable remission, minimal
manifestation) clinical status (>1 year), (ii) repopulation of the B cell compartment after
RTX, and (iii) disease relapse following sustained CSR/MM after rituximab (9, 53).
Selected patients may have been treated with RTX prior to study entry. All pre-RTX
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sample collection time points precede post-RTX time points by at least one infusion of
RTX. An additional asymptomatic (by Myasthenia Gravis Foundation of America or
MGFA classification score) AChR MG control subject was also included.

Bulk library Preparation
RNA was prepared from frozen peripheral blood mononuclear cells using the RNAEasy
Mini kit (Qiagen) per manufacturer’s instructions. Cells were pelleted and lysed in
freezing media without washing to preserve cell populations sensitive to
cryopreservation. RNA libraries were made using reagents supplied by New England
Biolabs (a gift from Drs. Eileen Dimalanta and Chen Song, Ipswich, Massachusetts) as
part of the NEBNext ® Immune Sequencing Kit. IGH library preparation and sequencing
was performed in the same manner as previously published using only primers targeting
IGHA, IGHD, IGHE, IGHG and IGHM regions (99).

Raw read quality control and assembly for bulk libraries
Bulk repertoire data processing and analysis was carried out using tools in the
Immcantation framework (http://immcantation.org). Preprocessing was carried out using
pRESTO v0.5.10 (100) as follows. 1) Reads with a mean Phred quality score below 20
were removed. 2) Reads were aligned against constant region primer and template switch
sequences, with a maximum mismatch rate of 0.2 and 0.5 respectively. Reads failing to
match both a constant region primer and template switch sequence were removed. 3)
Remaining reads were grouped based on unique molecular identifier (UMI) sequences
determined by the 17 nucleotides preceding the template switch site. 4) Separate
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consensus sequences for the forward and reverse reads within each UMI group were
constructed with a maximum error score of 0.1 and minimum constant region primer
frequency of 0.6. If multiple constant region primers were associated with a particular
UMI group, the majority primer was used. 5) Forward and reverse consensus sequence
pairs were aligned to each other with a minimum overlap of 8 nucleotides and a
maximum mismatch rate of 0.3, and assembled into full length sequences. Sequence pairs
that failed to align to each other were assembled by alignment against the IMGT human
germline IGHV reference database (IMGT/GENE-DB v3.1.19; retrieved June 21, 2018;
Giudicelli et al. 2005) with a minimum overlap of 0.5 and a E-value threshold of 1x10-5.
6) Isotypes were assigned by local alignment of the 3’ end of each consensus sequence to
isotype-specific constant region sequences with a maximum mismatch rate of 0.4. 8)
Duplicate sequences were removed, except those spanning multiple biological samples
and/or with different isotype assignments. Constant region primers, isotype-specific
internal constant region sequences, and template switch sequences used are available at:
https://bitbucket.org/kleinstein/immcantation/src/default/protocols/AbSeq.

Single-cell library preparation and gene expression analysis
B cells were isolated from PBMCs by EasySepTM Human Pan-B cell Enrichment Kit
(immunomagnetic negative selection kit, StemCell) per manufacturer’s instructions.
Additional fluorescence-activated cell sorting (FACS) was then performed; B cells
labelled with 7AAD Viability Staining Solution (BioLegend) and FITC-labelled anti-IgD
antibody (mouse anti-human monoclonal antibody, BioLegend clone IA6-2) were
removed to exclude non-viable cells and all naïve B cell populations. Sorted B cells were

32

then loaded into the Chromium Controller (10x Genomics). Single cell gene expression
libraries were prepared using the Chromium Single-cell 5′ Reagent Kit (10x Genomics)
for version 1 chemistry per the manufacturer’s protocol. Samples were sequenced on the
NovaSeq with 100x100 or 150x150 paired end reads for gene expression and BCR
libraries respectively. Base calls were converted to fastq sequences and demultiplexed
using the cellranger mkfastq function from 10X Genomics 2.2.0 and aligned to the
GCRhg38 genome supplied by 10X Genomics. Sparse count matrices, barcode
assignments and feature calls were prepared using the cellranger count function. Seurat
v.2.3.4 was used for gene expression analysis. Cells with less than 50 genes detected,
mitochondrial content above 0.2 of all transcripts or expressing detectable CST3, CD3E,
KLRB1, NKG7 and GATA2 transcripts (to remove non-B cell populations like T cells and
myeloid cells) were excluded. Single-cell gene expression values were computed from
log normalized count values (101). 12,534 cells were identified after filtering. tSNE was
computed after identifying highly variable genes using FindVariableGenes and correcting
for batch effects using the first 20 dimensions from canonical correlation analysis after
visualization of components with MetageneBicorPlot. The first 10 dimensions were used
for PCA based on the location of the inflection point from PCElbowPlot. FindClusters
was then used to identify clusters in Seurat v.2 which uses shared nearest neighbor
clustering (101).

Cell subsets were identified using a “basis set” of published marker genes called
immunoStates (102). The mean expression of each gene was computed for each cluster
from the scaled log normalized expression values; each cluster was then assigned to the
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immunoState subset with the highest Pearson correlation coefficient. The absence of
transitional B cells in the immunostates dataset meant this cluster was identified manually
using marker genes alone. Small clusters with elevated expression of mitochondrial
associated genes were also excluded from further analysis. We confirmed our
assignments by visualizing the expression of known gene expression markers for
instance, CD27 (for memory B cells), MS4A1 (CD20, for B cells in general except
plasma cells), MME (CD10, for transitional B cells) and PRDM1 (BLIMP1 for plasma
cells) (Figure S7A-C). Overall marker expression was also visualized based on the
percent of cells in each cluster expressing the gene and the overall mean level of gene
expression in each cluster (Figure S7D,E). To further confirm the identities of these
single-cell clusters, we assessed their paired IGH repertoire features for mean somatic
hypermutation (SHM) frequency and isotype usage which were consistent with expected
values (Figure S7F,G).

Bulk BCR repertoire V(D)J gene annotation, additional sequence filtering, clonal
assignment and germline reconstruction for Single-cell tracing of adaptive immune
repertoires (STAIR)
Reconstructed V(D)J sequences from single cell sequencing were extracted using the
cellranger vdj function from fastq reads. Single-cell V(D)J BCR repertoires as well as
previously published single-cell PCR (scPCR) derived V(D)J sequences were pooled
with bulk V(D)J BCR repertoires (9, 53). V(D)J germline assignments were made with
IgBLAST v1.7.0 (103) using the June 21, 2018 IMGT reference gene database from all
repertoires. Cells with multiple IGH V(D)J sequences were assigned to the most
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abundant IGH V(D)J sequence by UMI count. Only functional V(D)J sequences were
assigned into clonal groups using Change-O v0.3.4 (56). Sequences were first partitioned
based on common IGHV and IGHJ gene annotations, and junction lengths. Within
groups, sequences differing by a length normalized Hamming distance of 0.126 were
defined as clones by single-linkage clustering. This distance threshold was determined
based on the average local minima between the two modes of the within-sample bimodal
distance-to-nearest histogram for the three patients across multiple time points; thresholds
were determined using a kernel density estimate in the same manner described previously
(56). Germline sequences were then reconstructed for each clonal cluster (VH) with D
segment and N/P regions masked (replaced with Ns) using the CreateGermlines.py
function within Change-O v0.3.4.

Differential gene expression analysis
Single-cell expression values were imputed using the ALRA algorithm to account for
dropout (104). Any gene with a mean expression value less than 0.1 across all cells after
imputation was excluded. The gene expression of each gene per cell was subtracted by
the mean expression of the gene for that sample; the average expression of each gene was
then calculated for all cells of a given status (e.g. persistent vs non-persistent) to generate
a matrix of pseudobulk expression values. This matrix was further z-score normalized by
status. Paired student’s t-tests were performed to assign p-values. False detection rate
(FDR) correction was performed using Storey’s method implemented within the qvalue
package v3.9 in R from Bioconductor (for 12,066 p-values from cluster 3 associated
genes) (105). The enrichr package v1.0 in R was used for gene ontology analysis which
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implements a wilcoxon signed rank test for significance (106). A q-value (corrected pvalue) threshold of 0.05 was used for assigning significance.

CITE-Seq data used to investigate the association between CD20 mRNA (MS4A1) and
surface protein expression levels were downloaded from the source publication (patients
were healthy, between 18 and 45 and derived from a study on influenza vaccination, and
samples were collected as frozen PBMCs; a set of 10 patient samples were examined)
(63). A cluster corresponding to non-ASC B cells (cluster K1) was extracted from the
data object (cells from cluster C3), mRNA was normalized for each sample by z-score (as
above). Cells were identified as CD20 mRNA high or low based on whether they fell
above or below the 50th percentile in terms of CD20 mRNA expression, respectively.

Analysis of SHM, diversity and clonal overlap from BCR repertoires
Mutations relative to the germline sequence were quantified using ShazaM v0.1.8 in R
v3.4.2 (107). Diversity analysis was performed using Alakazam v0.2.11 and assessed
using the generalized Hill index, with uniform downsampling (to the number of V(D)J
from the sample with the fewest sequences to account for different sequencing depth) and
2,000 replicates of bootstrapping from the inferred complete clonal abundance (108).
Clonal overlap was computed using a Bray-Curtis metric implemented by the function
scipy.spatial.distance.braycurtis in scipy v1.1.0 (109).

Inference of B cell lineage trees and prediction of intermediate timepoints
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B cell lineage tree topologies and branch lengths were estimated using the dnapars
program distributed as part of PHYLIP (v3.697) (110). A maximum parsimony algorithm
was used to label the internal nodes of each lineage tree as either or pre-RTX, post-RTX,
given the date of sampling of each sequence at the tree’s tips. This was accomplished
using an implementation of the Sankoff parsimony algorithm (111) in which switches
from post-RTX to pre-RTX are forbidden using a cost matrix that weights post-RTX to
pre-RTX switches as 1000 times more costly than switches in the opposite direction.
Clusters of internal nodes separated by zero length branches (polytomies), were reordered using nearest-neighbor interchange (NNI) moves to minimize the number of
label switches along the tree. These analyses were performed using IgPhyML v1.1.1
(112). Trees were visualized using the R packages ape v5.3 (113) and ggtree v2.0.4
(114).

Statistics
R v.3.4.2 (107) and Python 3.5.4 was used for all statistical analysis (while phylogenetic
analysis was performed using R v3.6.3). Dataframe handling and plotting was performed
using functions from the tidyverse v1.2.1 in R and pandas v0.24.2, scipy v1.1.0 and
matplotlib v2.2.2 in python. All parametric statistical testing aside from that used for
differential gene expression analysis (described previously) was performed in R using the
aov function for two-way ANOVA or t.test functions for paired two-tailed student t-tests
(or one-tailed when appropriate). A significance threshold of p<0.05 was shown on plots
with a single asterisk; double asterisks correspond to a p <0.01 and triple asterisks
correspond to a p<0.001. P-values less than 0.05 were considered significant. Error bars
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are not presented in our analysis; violin plots are shown to highlight the full range of the
distribution for all figures instead.

Study Approval
This study was approved by Yale University's Institutional Review Board. Informed
consent was received from all participating patients prior to inclusion in this study.

Data Availability
Raw sequencing data in this study are available in the National Center for Biotechnology
Information’s Gene Expression Omnibus (GEO) database through GEO series accession
number GSE149133.

Figures and legends:
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Figure 1. Schematic diagram showing overall workflow from clinical data elements and
sample collection to computational analysis of BCR repertoires along with a timeline of
sample collection dates. (A) Three approaches were used for sequencing. First, bulk
repertoires using next-generation sequencing by isolating unpaired IGH V(D)J sequences
directly from RNA were generated. Second, paired heavy and light chain V(D)J
sequences from circulating B cells expressed as recombinant antibodies and tested for
antigen specificity were traced to pre-RTX repertoires. Finally, paired transcriptome and
heavy and light chain V(D)J sequence repertoires from high-throughput emulsion-based
single cell sequencing was performed. These three types of repertoires were analyzed
together in our analysis workflow for each patient across the sampled time points. (B)
Timeline of clinical events, specimen collection and B cell analysis for three MG patients
who experienced post-RTX relapses. Infusion describes a time point associated with a
recorded infusion of RTX. Post-RTX describes an event associated with a disease
exacerbation during which B cells were observed to secrete MuSK-specific
autoantibodies. Pre-RTX describes any collection time pointing preceding Post-RTX by
an intervening infusion event. Dates of events are approximations.
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Figure 2. B cell clones that overlap pre-RTX and post-RTX bulk IGH repertoires (i.e.,
persistient clones) are associated with switched isoptypes and increased somatic
hypermutation frequency. (A) Venn diagrams show counts of clones present at pre-RTX
and post-RTX time points and those that overlap both time points for all study subjects
(the relative area of each circle corresponds to the proportion of clones found at different
time points for each patient). (B) Shared B cell clones between pre-RTX and post-RTX
time points quantified as Bray-Curtis overlap for the same patient (intra-patient) or across
different patients (inter-patient). Horizontal bars show the mean overlap of each
comparison. A one-tailed t-test was used to assess the significance of the null hypothesis
that intra-patient overlap was not higher than inter-patient overlap. Overall distribution of
frequencies of different isotypes (C) and average somatic hypermutation frequencies (D)
among the set of sequences belonging to persistent and non-persistent clones during postRTX relapse for study subjects. Two-way ANOVA was performed to assess significance
for an overall somatic hypermutation frequency difference and isotype usage frequency
difference between non-persistent compared to persistent clones across isotypes;
specifically the effect of isotype, persistence and interaction between the two was
assessed for significance. Post-hoc two-tailed t-tests were also performed although no
significant differences were observed in (C) and (D). Data for the same n=3 patients are
shown for all panels. Violin plots are used in place of error bars to show the full range of
values. Statistical differences are shown only when significant (****P < 0.0001; ***P <
0.001; **P < 0.01; *P<0.05).
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Figure 3. Example lineage tree of a disease-relevant B cell clone spanning both the preand post-RTX repertoire. Sequences isolated from plasmablasts using single-cell PCR
(scPCR) sequencing-based approaches and tested as monoclonal antibodies are denoted
as "Plasmablast scPCR" (black dots); three of these bind MuSK and are denoted as
“MuSK binding” (black arrows). Lineage tree topology and branch lengths were
estimated using maximum parsimony, with edge lengths representing the expected
number of nucleotide substitutions per site (see scale) as estimated using dnapars v3.967
(110). Tips are colored by antibody isotype, and each internal branch is colored by
whether its descendant node was determined to have occurred in the pre- or post-RTX
repertoire using a constrained maximum parsimony algorithm (see Methods).
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Figure 4. Persistent B cell clones are disproportionately represented by the ASC
phenotype. (A) Unbiased clustering of single-cell transcriptomes from all study subjects
is visualized by t-SNE and colored based on B cell subset assignment. (B) V(D)J
sequences associated with persistent B cell clones are visualized over the tSNE plot
labelled in (A). B cells are colored black or red if the heavy chain V(D)J sequence paired
with the cell is part of a persistent B cell clone. B cells are colored red if the heavy chain
V(D)J sequence paired with the cell has the exact same V(D)J sequence as one present in
a pre-RTX bulk repertoire, and black if the clonal relative differs by one or more SHM.
(C) The relative fractions of persistent compared to non-persistent B cells for the memory
B cell cluster compared to ASC cluster. A one-tailed t-test was used to assess the
significance of the null hypothesis that ASCs would not be enriched compared to
memory B cells. Horizontal bars show the average frequency of a given B cell subset
across patients. Frequencies belonging to the same patient are paired with a gray line.
Data for the same n=3 patients are shown for all panels. Violin plots are used in place of
error bars to show the full range of values. Statistical differences are shown only when
significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure 5. Unique characteristics of persistent ASCs. (A) Expression of log normalized
CD20 expression (z-score) visualized by intensity over t-SNE plot. (B) The expression of
CD20 (the receptor target of rituximab gene symbol, MS4A1) and BAFF or APRIL
receptors (TACI or TNFRSF13B; BAFF-R or TNFRSF13C; BCMA or TNFRSF17) for
persistent and non-persistent members of the ASC cluster. Normalized gene expression
values are computed from counts of gene expression transcripts. Paired two-tailed t-tests
were used to test for the significant differential expression of each gene. Horizontal bars
show the average expression of ASC cluster members for each patient for cells of a given
status. (C) Clonal expansion expressed as Simpson’s diversity for ASC and memory B
cell clusters. A one-tailed t-test was used to assess the significance of the null hypothesis
that ASCs would not be less diverse than memory B cell clones. Horizontal bars show the
average diversity of cluster members for each patient of memory B cells or ASCs. (D)
Simpson’s diversity for persistent and non-persistent members of the ASC cluster. A onetailed t-test was used to assess the significance of the null hypothesis that persistent
clones would not be less diverse than non-persistent clones. Horizontal bars show the
average diversity of ASC cluster members for each patient for cells of a given status. (E)
The frequency of ASCs in post-RTX MuSK MG patients and a control AChR MG
patient. The fraction of ASC cluster members is quantified as a ratio of of the number of
cells in the ASC cluster divided by the number of total B cells for each patient. A one
sample t-test was used to assess the significance that ASCs would not be more abundant
in post-RTX samples compared to the asymptomatic AChR MG patient sample.
Horizontal bars show the average frequency of ASC cluster members for each patient of a
given status. Values belonging to the same patient are paired with a gray line for all
graphs. Data for the same n=3 patients are shown for all panels except panel (E) which
includes an asymptomatic patient sample (n=4). Violin plots are used in place of error
bars to show the full range of values. Statistical differences are shown only when
significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure 6. Memory B cells have distinct transcriptional and repertoire features associated
with persistence. (A) The normalized gene expression of CD20 (the receptor target of
rituximab gene symbol, MS4A1) and BAFF or APRIL receptors (TACI or TNFRSF13B;
BAFF-R or TNFRSF13C; BCMA or TNFRSF17) is presented for persistent and nonpersistent members of the memory B cell cluster for each patient for cells of a given
status. Normalized gene expression values are computed from counts of gene expression
transcripts. Paired two-tailed t-tests were used to test for the significant differential
expression of each gene. (B) Individual SHM frequencies for persistent compared to nonpersistent cells are presented for memory B cell cluster members. Only mean SHM
frequencies are computed for isotypes with more than three V(D)J sequences. Horizontal
bars show the average somatic hypermutation frequency for a given cluster. Paired twotailed t-tests were used to assess the significance of differences in mutation frequency.
(C) Overall constant region usage frequencies are quantified for persistent compared to
non-persistent memory B cell cluster members per patient. Horizontal bars show the
average frequency of constant region usage across patients. Two-way ANOVA was
performed to assess significance for an overall isotype usage difference between nonpersistent compared to persistent clones across isotype. Paired two-tailed t-tests were
used to assess the significance for the differential usage of each constant region. (D)
Clonal expansion expressed as Simpson’s diversity of persistent compared to nonpersistent memory B cell cluster members. A one-tailed t-test was used to assess the
significance of the null hypothesis that persistent clones would not be less diverse than
non-persistent clones. Horizontal bars show the average diversity of memory B cell
cluster members for each patient of a given status. Values belonging to the same patient
are paired with a gray line for all graphs in this panel. Data for the same n=3 patients are
shown for all panels. Violin plots are used in place of error bars to show the full range of
values. Statistical differences are shown only when significant (****P < 0.0001; ***P <
0.001; **P < 0.01; *P<0.05).
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Figure 7. Identification of B cell clusters associated with resistance to RTX depletion
(cluster 3). Visualization of initial shared nearest-neighbor (SNN) clustering of
circulating B cells post-RTX by t-SNE with labels over clusters (A). B cells that were
clonally related to cells in the pre-RTX repertoire are indicated (red dot if the pre- and
post-RTX V(D)J sequence is identical at the nucleotide level, and black dot otherwise)
(B). The frequency of each cluster (by cell) among the set of persistent B cells is shown
(C). The expression of the receptor target of rituximab CD20 (MS4A1) is presented for
members of cluster 3 and members of other memory B cell clusters (D). The expression
of known receptors for BAFF and APRIL (TACI or TNFRSF13B; BAFF-R or
TNFRSF13C; BCMA or TNFRSF17) is also presented. Differential epression of each
gene was assesed using paired two-tailed t-tests. Horizontal bars show averages, with
values belonging to the same patient paired with a gray line. Data for the same n=3 patients
are shown for all panels. Violin plots are used in place of error bars to show the full range of
values. Statistical differences are shown in (D) (****P < 0.0001; ***P < 0.001; **P <

0.01; *P<0.05).
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Supplemental Information

Patient

1

2

3

Age

Sex

Collection

Event Type

Antibody
Titer

MGFA Class

6

Pre-RTX

1:2560

I1

2

Pre-RTX

1:2560

IIa

7

Pre-RTX

1:5120

IIIb

10

Post-RTX

5.70
nmol/L4

IIb

3

Pre-RTX

1:2560

IIb

8

Pre-RTX

1:2560

Asymptomatic2

9

Post-RTX

1:5120

IIb3

1

Pre-RTX

1:160

IIa

5

Pre-RTX

<1:10

IIa

12

Pre-RTX

<1:10

IIa

4

Post-RTX

0.89
nmol/L4

IIa

37 F

63 F

53 F

Table S1. Clinical characteristics of MuSK MG study subjects at each collection time
point. The Myasthenia Gravis Foundation of America (MGFA) clinial classification
divides MG into five classes (I-V) based on signs and symptoms of disease severity.
Reported age is at time of “Post-RTX” relapse.
1

Patient reported mild intermittent fatigable limb weakness prior but none on day of
exam/collection, except for mild non-fatigible unilateral ptosis.
2
Complete Stable Remission (CSR); patient with clinical relapses 2 months later.
3
Patient with clinical relapse/exacerbation
4
MuSK Antibody Level (reference range: positive > 0.02 nmol/L || Mayo Clinical
Laboratory, USA). MuSK Antibody Titer (reference range: positive ³ 1:20 || Athena
Diagnostics, USA) is reported for all others as this was the only or preferred commercial
lab available at the time of collection.

47

Patient

Collection

Relapse

6

Pre-RTX

2

Reads

Unique IgM

Unique IgG

Unique IgA

Clones

321622

19552

25596

26067

20084

Pre-RTX

339025

11995

40274

33127

15015

7

Pre-RTX

518947

29872

23544

26715

31820

10

Post-RTX

810822

30492

12343

14239

31902

3

Pre-RTX

391364

4274

971

2617

5290

8

Pre-RTX

108953

9477

1513

4154

10088

9

Post-RTX

460288

13823

2475

7788

14630

1

Pre-RTX

364381

752

5785

2392

2427

5

Pre-RTX

508120

29

669

1288

239

12

Pre-RTX

188934

154

2321

4016

860

4

Post-RTX

477305

7366

12952

10060

7999

1

2

3

Table S2. Counts of reconstructed V(D)J sequences by isotype and clones from
sequencing of pre-RTX and post-RTX bulk BCR repertoires.
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A

B

C

Figure S1. Distance-to-nearest plots used to identify a common threshold to use for
hierarchical clustering based grouping of V(D)J sequences from high throughout
sequencing of BCR repertoires. Red dashed lines corresponds to the threshold used for
assigning clonal clusters. Dark grey bars represent the distribution of intra-subject
distance-to-nearest distances while light grey bars represent the distribution of intersubject distance-to-nearest distances.
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Figure S2. Persistent B cell clones do not show evidence of significant clonal expansion
or accumulation of somatic hypermutations when comparing pre-RTX and post-RTX
members. The presence of increases in overall somatic hypermutation for individual
clones is quantified by comparing the average SHM frequency of each clone in the preRTX vs. post-RTX repertoire (A-C). Ratios are visualized as a histogram of the log2 fold
changes in somatic hypermutation frequency values for these clones for each patient. Red
dashed lines correspond to the median of each distribution. The presence of clonal
expansions is evaluated by comparing the overall frequency of individual persistent
clones at the post-RTX time point vs. the pre-rituximab time point (D-F). Frequencies are
computed as a fraction of total unique V(D)J sequences and visualized in terms of a
histogram of the log2 changes in total frequency for these clones. Red dashed lines
correspond to the median of each distribution for each patient.
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Stathopoulos et al. 2017, BCR sequences from scPCR of circulating plasmablasts (ref 9)
Patient

Clones

Traceable clones

Pre-RTX clones

1

4

3

1

2

0

0

0

3

39

19

5*

Takata et al. 2019, BCR sequences from scPCR of tetramer binding B cells (ref 59)
Patient

Clones

Traceable clones

Pre-RTX clones

1

22

3

1

2

4

0

0

3

12

2

0

Table S3. Count of plasmablast derived or tetramer-binding V(D)J sequences clonally
related to members of the pre-RTX or post-RTX bulk BCR repertoire (Traceable clones)
or to members of the pre-RTX and post-RTX bulk BCR repertoire (Pre-RTX clones).
*One clone was observed to also correspond to a clone previously published to have
specificity for MuSK autoantigen. The strongest binding member of this clone was
annotated as “3-29” in the previous publication.
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Clone ID: 3-3

Clone ID: 3-25

Constant
Region
IgM
IgA
IgG
scPCR

Post-RTX
Pre-RTX

0.05

0.05

Figure S3. Clonal lineages containing scPCR-derived antibodies from Sanger sequencing
identified in post-RTX repertoires. Maximum parsimony trees corresponding to clones
that contain scPCR derived V(D)J sequences, and that have clonal variants present preRTX and post-RTX are presented. Sequences isolated using scPCR-based approaches
from plasmablasts are denoted as "scPCR" using a large black dot and arrow along with
the corresponding identity of the antibody from Stathopoulos et al. 2017 (ref. 15 in main
manuscript). Edge lengths are quantified based on number of intervening somatic
52

hypermutations per site between observed V(D)J sequences per the scale. Colors
correspond to whether each V(D)J sequence was collected from a pre-RTX or post-RTX
time point (or both) and also the associated constant region.
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Clone ID: 3-31

Constant
Region
IgM
IgA
IgG
scPCR

Post-RTX
Pre-RTX

0.05

54

Figure S4. Clonal lineages containing scPCR-derived antibodies from Sanger sequencing
identified in post-RTX repertoires. A maximum parsimony tree corresponding to a clone
that contains scPCR derived V(D)J sequences, and that have clonal variants present preRTX and post-RTX is presented. Sequences isolated using scPCR-based approaches from
plasmablasts are denoted as "scPCR" using a large black dot along with the
corresponding identity of the antibody from Stathopoulos et al. 2017 (ref. 9). Edge
lengths are quantified based on number of intervening somatic hypermutations per site
between observed V(D)J sequences per the scale. Colors correspond to whether each
V(D)J sequence was collected from a pre-RTX or post-RTX time point (or both) and also
the associated constant region.

55

Clone ID: 3-26

Clone ID: 1-2

0.05

0.05

Clone ID: MuSK1-7

Constant
Region
IgM
IgA
IgG
scPCR

Post-RTX

0.05

Pre-RTX

Figure S5. Clonal lineages containing scPCR-derived antibodies from Sanger sequencing
identified in post-RTX repertoires. Maximum parsimony trees corresponding to clones
that contain scPCR derived V(D)J sequences, and that have clonal variants present pre56

RTX and post-RTX are presented. Sequences isolated using scPCR-based approaches
from plasmablasts are denoted as "scPCR" using a large black dot along with the
corresponding identity of the antibody from Stathopoulos et al. 2017 (ref. 9). Of note, the
sequence associated with clone “MuSK1-7” was published in Takata et al. 2019 (ref. 59)
and was isolated using an antigen-specific tetramer. Edge lengths are quantified based on
number of intervening somatic hypermutations per site between observed V(D)J
sequences per the scale. Colors correspond to whether each V(D)J sequence was
collected from a pre-RTX or post-RTX time point (or both) and also the associated
constant region.
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Patient

Collection

Control

A
1

10

2

9

3

4

Status
AChR MG
Asymptomatic
MuSK MG PostRTX
MuSK MG PostRTX
MuSK MG PostRTX

Read
Count

Cell Count

Mean Reads
per Cell

Median
Genes per
Cell

VDJ Count

708747323

3580

197974

1499

3810

303494244

3550

85491

1189

2859

130365803

8502

15333

1130

6827

112260566

2501

44886

1790

1175

Table S4. Quality control from paired single-cell transcriptome and repertoire
sequencing.
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Figure S6. Example fluorescence activated cell sorting (FACS) gates for IgDlow B cells
used as input for single-cell transcriptomics and BCR repertoire analysis. Example is
shown for collection 10.
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Cluster

Immunostates Assignment

Pearson Correlation

Final Assignment

0

naive_B_cell

0.234

Mature Naive

1

memory_B_cell

0.125

Memory

2

memory_B_cell

0.122

Memory

3

memory_B_cell

0.166

Memory

4

memory_B_cell

0.251

Memory

5

memory_B_cell

0.351

Memory

6

naive_B_cell

0.136

Transitional

7

not_assigned

-0.230

8

plasma_cell

0.644

ASC

9

memory_B_cell

0.212

Memory

10

not_b_cell

0.063

Not B cell

11

not_assigned

-0.135

Not Assigned

Not Assigned

Table S5. Table of cluster assignments using the immunoStates basis set. Clusters were
assigned to the B cell immunostate with the maximum Pearson correlation coefficient
when compared with the mean expression value of genes associated with each cluster.
One naive B cell cluster was assigned to a transitional B cell subset based on marker
expression (cluster 6) and another cluster (cluster 10) was excluded owing to elevated
expression of mitochondrial genes.
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Figure S7. Assignment of B cell clusters based on single-cell transcriptome and repertoire
according to known B cell subsets. Plotting of gene expression of key marker genes over
t-SNE plot with intensity of shading correlated with amount of scaled log normalized
expression for (A) CD27 (B) CD10 (MME) and (C) BLIMP1 (PRDM1). Dot plot of
average log normalized expression (color) and fraction of cells expressing a set of marker
genes (size) presented for B cell subsets derived from unbiased clustering (D) and when
grouped into known B cell subset clusters (E). (F) Overall usage of different constant
regions by B cell subset as a fraction of all V(D)J sequences associated with each B cell
subset cluster per sample. Horizontal bars show the average frequency of constant region
usage across patients. Frequencies belonging to the same patient are paired with a gray
line. (G) Distribution of somatic hypermutation frequencies among all V(D)J sequences
assigned to each B cell subset cluster. Horizontal bars show the average somatic
hypermutation frequency for a given B cell subset cluster.
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Figure S8. Persistent and non-persistent ASCs are associated with similar V(D)J
repertoire features. Overall constant region usage frequencies are quantified for persistent
compared to non-persistent cells for the (A) ASC cluster per patient. Horizontal bars
show the average frequency of constant region usage across patients. Frequencies
belonging to the same patient are paired with a gray line. Individual SHM frequencies for
persistent compared to non-persistent cells are presented for ASC cluster members (B).
Only mean SHM frequencies are computed for isotypes with more than 3 V(D)J
sequences. Horizontal bars show the average somatic hypermutation frequency for a
given cluster. Frequencies belonging to the same patient are paired with a gray line.
Statistical differences are shown only when significant (****P < 0.0001; ***P < 0.001;
**P < 0.01; *P<0.05).
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Figure S9. Persistent ASC and memory B cell clones do not show evidence of significant
clonal expansion or accumulation of somatic hypermutations when comparing pre-RTX
and post-RTX members. The presence of increases in overall SHM for individual clones
is quantified by comparing the SHM frequencies averaged for each clone in the pre-RTX
repertoire compared with post-RTX and visualized in terms of a histogram of the natural
log change in somatic hypermutation frequency for each clone for each patient. Red
dashed lines correspond to the median of each distribution for each patient. The set of
clones examined is filtered for clones associated with ASCs (A) or memory B cells (B).
The presence of clonal expansions is evaluated by comparing the overall frequency of
individual persistent clones at the post-RTX time point compared to the pre-RTX time
point from bulk IGH repertoires as a fraction of total unique V(D)J sequences and
visualized in terms of a histogram of the natural log change in total frequency for these
clones. Red dashed lines correspond to the median of each distribution for each patient.
The set of clones examined is filtered for clones associated with ASCs (C) or memory B
cells (D). The median of either the change (E) in clonal somatic hypermutation
frequencies or clonal size distribution (F) associated with each patient is presented for
each filtering strategy ("Total" for no filtering, "ASC" for filtering of ASC associated
clones or "Memory" for filtering of Memory B cell associated clones. Horizontal bars
show the median natural log change in clonal size or clonal somatic hypermutation
frequency across patients. Values belonging to the same patient are paired with a gray
line.
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Surface CD20 Expression
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Figure S10. Elevated expression of surface CD20 for B cells with high CD20 mRNA
expression. Single cells in the B cell cluster (excluding plasma cells) for each of six
subjects in the dataset from Tsang et al. (ref. 30 in main manuscript) were split into high
(top 50th percentile) and low (bottom 50th percentile) groups based on CD20 mRNA
expression. The mean expression of surface CD20 is presented for each of these groups
in each individual sample. Normalized gene expression values are computed from scaled
log normalized counts of barcoded transcripts aligned to the CD20 gene. Horizontal bars
show the average normalized gene expression across subjects. Expression values
belonging to the same subject are paired with a gray line. Statistical differences are
shown only when significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure S11. Cluster 3 has distinct transcriptional and V(D)J repertoire features. (A) The
expression of plasma cell associated genes (CD38; BLIMP1 or PRDM1) is also presented
for members of cluster 3 and members of other memory B cell clusters. Normalized gene
expression values are computed from scaled log normalized counts of barcoded
transcripts aligned to each gene. Horizontal bars show the average normalized gene
expression across patients. Expression values belonging to the same patient are paired
with a gray line. (B) Mean somatic hypermutation frequencies for cluster 3 compared to
other memory B cells is quantified per patient. Horizontal bars show the average somatic
hypermutation frequency for a given set of cells. Frequencies belonging to the same
patient are paired with a gray line. (C) Overall constant region usage frequencies are
quantified for cluster 3 compared to other memory B cells per patient. Horizontal bars
show the average frequency of constant region usage across patients. Frequencies
belonging to the same patient are paired with a gray line. (D) Simpson’s diversity of
cluster 3 members compared to other memory B cell cluster members. Statistical
differences are shown only when significant (****P < 0.0001; ***P < 0.001; **P < 0.01;
*P<0.05).
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Figure S12. Cluster 3 memory B cells have a distinct gene signature. Heatmap of
significantly differentially expressed genes for cluster 3 compared to other memory B
cells, with a greater than >0.4 z-score difference between persistent and non-persistent
labels.
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Figure S13. Cluster 3 memory B cells have a MYC and p53/BRCA1 signature.
enrichR gene ontology analysis of either genes up-regulated among cluster 3 memory B
cells compared to other memory B cells. Only differentially expressed genes with an
adjusted p-value less than 0.05 with FDR correction by Storey’s method were evaluated.
Red bars correspond to significantly associated gene ontology assignments (p < 0.05 by
wilcoxon signed rank test).
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Figure S14. Cluster 3 memory B cells have a MYC and p53/BRCA1 signature.
enrichR gene ontology analysis of either genes down-regulated among cluster 3 memory
B cells compared to other memory B cells. Only differentially expressed genes with an
adjusted p-value less than 0.05 with FDR correction by Storey’s method were evaluated.
Red bars correspond to significantly associated gene ontology assignments (p < 0.05 by
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Figure S15. Visual model outlining the likely source of antigen-specific B cells during
post-RTX relapse as shown in our study. Blue cells represent antigen-specific B cells
whereas orange cells represent non-antigen specific B cells.
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Abstract
We speculate that thymus-associated B cells and plasma cells persist in the circulation
after thymectomy and that their persistence could explain incomplete responses to
resection. We studied patients enrolled in a randomized clinical trial and used
complementary modalities of B cell repertoire sequencing to characterize the thymus B
cell repertoire and identify B cell clones that resided in the thymus and circulation before
and 12 months after thymectomy. Thymus-associated B cell clones were detected in the
circulation by both mRNA-based and gDNA-based sequencing. These antigenexperienced B cells persisted in the circulation after thymectomy. Many circulating
thymus-associated B cell clones were inferred to have originated and initially matured in
the thymus before emigration from the thymus to the circulation. The persistence of
thymus-associated B cells correlated with less favorable changes in clinical symptom
measures, steroid dose required to manage symptoms and marginal changes in AChR
autoantibody titer. This investigation indicates that the diminished clinical response to
thymectomy is related to persistent circulating thymus-associated B cell clones.
Keywords: Myasthenia gravis, thymectomy, B cells, autoimmune disease, adaptive
immune cell receptor repertoire sequencing
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Introduction
Myasthenia gravis (MG) is a neuromuscular disorder caused by autoantibodies targeting
components of the neuromuscular junction. Patients with MG experience skeletal muscle
weakness, worsened by activity (115, 116). In upwards of 85% of MG patients,
autoantibodies specifically target the nicotinic acetylcholine-receptor (AChR) (116).
Many clinical and experimental studies, including maternal-to-fetal transfer, plasma
exchange to deplete antibodies, and passive transfer of patient-derived immunoglobulin
show that AChR autoantibodies are demonstrably pathogenic (115, 117–124). AChRmediated signal transmission is impaired by a number of autoantibody-mediated
functions. AChR autoantibodies are predominantly IgG1 and IgG3; two subclasses that
effectively activate complement (125–127). Thus, complement-mediated tissue injury
and consequent removal of AChR from the muscle membrane represents a major
mechanism of immunopathology. Additional mechanisms include autoantibody-mediated
antigen cross-linking, resulting in internalization of AChR (by modulating
autoantibodies), and a direct blocking of the acetylcholine binding site by the
autoantibodies (128–133).

A key source of these pathogenic AChR autoantibodies in MG patients is the MG
thymus. Thymic lymphofollicular hyperplasia (28) with germinal centers is observed in
approximately 70% of younger MG patients (134). The thymus in these patients contains
both AChR-specific IgG (135) and B cells (136) that can secrete these autoantibodies
(20). Transplantation of thymus from AChR-MG patients into immunodeficient mice
results in human AChR-specific autoantibody deposits at the neuromuscular junction, and
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subsequent manifestation of MG-like symptoms (23). Thymus-associated plasma cells
and plasmablasts spontaneously produce AChR autoantibodies in vitro (137, 138) and
activated memory B cell populations (139–141). B cells residing in the hyperplastic
thymus organize within tertiary lymphoid organs forming structures that share many
characteristics associated with germinal centers (2, 142–144). The presence and
frequency of these structures positively associates with the presence of circulating AChR
autoantibodies (32). Expanded clones among the MG thymus resident B cells is
consistent with the presence of ongoing germinal center-based maturation processes (24,
145). These clones feature the characteristics of antigen experience, including isotype
class switching, somatic hypermutation and biased usage of antibody variable region
gene segments (24, 146–149).

These collective studies clearly demonstrate that the thymus plays a fundamental role in
the production of AChR autoantibodies and consequently the immunopathology of MG.
Based only on empiric clinical evidence, thymectomy had already been widely used as a
long-standing treatment strategy for AChR autoantibody-positive MG (150). A multicenter, single-blind, randomized clinical trial (MGTX) designed to evaluate the efficacy
of thymectomy plus prednisone versus prednisone alone in generalized non-thymomatous
AChR-MG was recently performed to formally test the effect of thymectomy (27). The
study demonstrated the efficacy of thymectomy as the procedure led to a significant
improvement in muscle weakness, decreased steroid usage and a decreased frequency of
re-hospitalization over the course of 3 years. Results from a two-year extension study of
the MGTX trial (22) demonstrated that the patients who underwent thymectomy were
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more likely to have a better clinical status compared to patients who were treated with
prednisone alone. Moreover, therapeutic effects from thymectomy continue to be
observed years after the procedure, but some patients experienced more benefit than
others. These findings are consistent with other studies, which showed rates of complete
stable remission in only 40-50% of patients when followed for years after the procedure
(33, 34). Furthermore, the AChR autoantibody titer decreases in the majority of those
treated by thymectomy, but almost never reaches undetectable levels (32, 151) and only
modestly decreases in many (152). Understanding both the mechanistic basis for
heterogeneous responses and why thymectomy does not consistently lead to complete
stable remission is therefore critical to improving the management of AChR autoantibody
positive MG patients with thymic lymphofollicular hyperplasia.

Given extensive evidence that disease-causing B cells in AChR-MG are found in the
thymus alongside clinical evidence showing heterogeneous responses to thymectomy, we
sought to test the possibility that B cell clones from the thymus persist in the periphery
after removal of the thymus. We hypothesized that B cell clones from the thymus would
be found in the circulation and that the persistence of these clones overall would correlate
with disease persistence. Thus, in this study, we test the hypothesis that the global
depletion of B cell clones from the thymus including those that produce AChR
autoantibodies is a mechanism by which thymectomy reduces disease burden. To test this
hypothesis, we performed adaptive immune receptor repertoire (AIRR) sequencing of B
cell receptor (BCR) repertoires from thymus and paired longitudinal peripheral blood
samples from the MGTX trial and an independent center, generating approximately half a
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million V(D)J sequences in total. AIRR sequencing (AIRR-Seq) has the capacity and
depth to identify rare sequences in the large (1011 B cells) circulating peripheral repertoire
found in humans (153). Consequently, this approach allowed us to identify rare B cell
clones in the circulation related to those in the thymus and track their frequency over time
after thymectomy.

Results
Patients, specimens and experimental design
Eight thymectomy-treated AChR-autoantibody positive MG subjects (7 female, 1 male;
mean age of 23.6 with standard deviation of 9.2 years, range 18–46) from the MGTX trial
(table 1) were selected for study. Matched specimens from each patient included (1)
mRNA and genomic DNA from PBMCs, which were isolated at the time of the resection
(referred to as baseline), (2) mRNA from PBMCs isolated 12 months after the
thymectomy, and (3) frozen intact thymus tissue specimens. In addition, a patient
(female, age 36) who underwent thymectomy at an independent tertiary care facility
unaffiliated with the MGTX trial was also included to assess the generalizability of our
findings (table 1). Matched specimens from this patient included mRNA from PBMCs,
which was isolated at the time of the resection and also six months after the thymectomy,
and intact thymus tissue specimens. Thymus specimens from all subjects were sectioned
and evaluated by histology and immunohistochemistry such that sections observed to
contain morphological features resembling B cell-enriched germinal centers were
specifically selected for sequencing (figs. S1, S2). High-depth AIRR sequencing was
performed using complementary mRNA and gDNA-based approaches. Experiments were
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designed to test whether B cell clones in the thymus were shared among those in the
circulation and how shared circulating clones behaved following thymectomy (fig. S3).

MG thymus resident B cells feature antigen-driven characteristics
The repertoire of B cells that reside in tertiary lymphoid organs, which are often found in
autoimmune tissue, have been observed to possess unique characteristics often associated
with a developing response to specific antigen(s). These qualities include, elevated
frequency of class-switching, elevated somatic hypermutation frequency and lower
replacement/silent mutation ratio i.e. increased signature of negative selection, elevated
frequency of N-glycosylation sites, and reduced frequency of VH3 gene usage (154, 155).
High-depth AIRR-Seq has not been applied to investigate whether these features are
consistently found in thymus from AChR-MG (AChR autoantibody positive MG)
patients where such tertiary lymphoid structures are present. Thus, we examined the
thymus B cell receptor repertoire for the enrichment of these same features by performing
mRNA-based AIRR-Seq on the eight MGTX trial-derived thymus specimens (table S1)
and paired repertoires from the circulation (derived from whole blood RNA collected at
baseline).

On average, the thymus B cell repertoire was 85.4% IgG switched compared to only
28.0% in the circulation (paired t-test P=1.3e-06) (fig. 1A). Correspondingly, the fraction
of IgM and IgA switched V(D)J sequences in the thymus-derived B cell repertoire was
significantly lower (paired t-test P=1.3e-03 and P=4.4e-04, respectively). The average
SHM frequency for IgM and IgA was not significantly different for thymus-derived B
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cells compared to those from the circulation. However, when restricting the analysis to
IgG switched V(D)J sequences (given the clear role of this isotype in MG), a consistent
elevation in SHM frequency for IgG switched B cells in the thymus (6.3% mutated) was
observed compared to the circulation (5.5% mutated) (paired t-test P=0.039) (fig. 1B). In
addition, we examined the ratio of replacement to silent mutations as this provides
information about features of antigen selection not provided by quantification of total
SHM frequency alone. Circulating and tissue-resident B cells from patients with
autoimmunity (as well as in the context of vaccination) have consistently been observed
to display a lower-than-expected ratio of replacement to silent mutations (99, 112, 155,
156). Negative selection pressure may favor the conservation of protein structure by
introducing mutations that preserve antibody amino acid sequence; this may be a key
feature of repertoires actively undergoing affinity maturation (112, 157). Thymus
samples were observed to contain B cells with lower selection strength than sequences
from circulating B cells (P=1.0e-9 for CDR, P=4.3e-2 for FWR regions) (fig. 1C) (157).

Several recent studies have also demonstrated an enrichment of variable region N-linked
glycosylation sites relative to healthy controls in B cells from the peripheral blood of
patients with rheumatoid arthritis (154) or in the parotid gland of patients with primary
Sjogren's syndrome, a structure also known to contain ectopic lymphoid follicles (155).
Consistent with these observations, we found that the thymus IgG-switched B cell
receptor sequences were more enriched than paired blood for N-linked glycosylation
DNA motifs, (frequency of 14.5% vs 6.9%, respectively; paired t-test P=0.008) (fig. 1D).
This frequency was also elevated for thymus IgM-expressing B cells but not for IgA
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(paired t-test P=0.037 and P=0.56 respectively). To investigate if the elevated frequency
of N-linked glycosylation sites was introduced through affinity maturation, we assessed
the frequency of these sites in the associated germline V genes and observed that a
difference in N-linked glycosylation frequency could no longer be detected (paired t-test
P=0.50) for thymus IgG-expressing B cells while the frequency for IgM was still elevated
(paired t-test P=0.019) (fig. 1E). This result indicates that N-linked glycosylation sites
were generated by affinity maturation and possibly due to antigen-driven selection for
IgG-switched B cells. Finally, we sought to investigate if IgG-switched B cells in the
thymus use a different set of V genes compared to those in the circulation. A significant
difference in terms of V family usage (ANOVA P=0.013) (fig. S4A) was observed.
Specifically, there was a decrease in the use of VH3 family genes and an increase in the
usage of VH4 family genes in the thymus IgG-switched B cell repertoire.

Collectively, these findings demonstrate that the thymus is highly enriched for
somatically mutated IgG-switched B cells with an elevated N-linked glycosylation site
frequency, signatures of negative selection, and biased usage of VH4 V family genes
compared to VH3 family genes. These are all features of mature antigen-driven B cells,
including plasma cells, which are likely to be disease-relevant. Furthermore, these
characteristics that are associated with an antigen-driven response are also found to be
enriched, albeit to a lesser degree, in the circulating B cells of MG patients (99).

Clonally related B cells reside in both the thymus and circulation
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We next sought to determine whether B cells present in MG thymus had clonal relatives
in the circulation. We define a B cell clone as a set of V(D)J sequences that arise from a
common immunoglobulin heavy chain (IGH) gene recombination event. Thus, V(D)J
sequences belonging to a clone share common IGHV, IGHJ and IGHD genes as well as a
set of N/P additions but may differ from each other due to sequence diversity introduced
by SHM. A threshold (18.8%) was used to define how different junction sequences from
the same clone could be among sequences sharing IGHV and IGHJ genes (fig. S5A-H). It
is possible that sequences from biologically distinct clones share sufficient sequence
similarity to be incorrectly grouped into the same clone however. To estimate the
frequency at which clones are spuriously observed to be shared between the circulation
and thymus, the average background sharing between the circulation and the thymus of
unrelated individuals was calculated. This rate was used as a null distribution to establish
the significance of the observed clonal sharing between the circulation and the thymus.
Seven of the eight MGTX patients were studied, due to insufficient sequencing depth for
clonal sharing analysis in one specimen (only 5070 thymus sequences). In these seven
patients, a mean of 482.9 clones (2.1% of all thymus clones) were found to be shared
between the thymus and circulation at baseline while a mean background of 90.6 clones
(0.6% of all thymus clones) were found shared between the same two compartments of
unrelated individuals (fig. S6A-G). The observed sharing was significantly higher than
the background for all thymus tissue samples studied (one-tailed paired t-test P=5.4e-4).
That is, more thymus clones were shared with the circulation of the same individual, than
that of unrelated individuals (fig. 2A).
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To further confirm these findings, we performed genomic DNA (gDNA)-based
sequencing of thymus and paired circulating pre-thymectomy blood specimens that were
different from those examined by mRNA-based sequencing. These unique specimens
were collected from three of the patients participating in the MGTX trial (fig. S7 table
S2). We sequenced gDNA and identified shared B cell clones; the analysis of sharing and
background sharing was then performed as above. Clonally related B cells residing in the
thymus and circulation could be detected across all three patients. Specifically, we found
21 (0.93% of all thymus clones), 10 (0.31%) and 1 (0.06%) shared clones respectively for
each of the three patients and an average background of 0.5 for each of the three patients
(0.02%, 0.03%, 0.02% respectively) (figs. 3A-F). Thus, these data from specimens,
examined using complementary sequencing approaches, collectively demonstrate that a
fraction of B cell clones residing in the thymus can also be found in the circulation prior
to thymectomy.

B cell clones shared between the thymus and circulation feature a distinct repertoire
We speculated that B cells in the circulation belonging to clones shared with the thymus
display the features that are characteristic of thymus-resident B cells. Specifically, that
they are more clonally expanded, more frequently class switched to IgG and have
accumulated more SHM than those that are not shared with the thymus. Therefore, we
investigated these features among clones shared between the thymus and circulation. We
first tested the hypothesis that B cells found in the circulation that are shared with the
thymus (referred to as “thymus-associated”) are clonally expanded to a greater extent;
given that antibody secreting cells and B cells responding to antigen typically have this
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characteristic. Clones in the circulation shared with the thymus were confirmed to be
more clonally expanded (larger clone size) when compared to clones in the circulation
that were not shared (paired t-test P=0.042) (fig. 4A).

We next investigated the overall isotype distribution of clones in the circulation shared
with the thymus. Given that thymus-resident clones are disproportionately IgG-switched,
we speculated that thymus-associated clones would also be more IgG-switched. A large
fraction (41.3%) of circulating clones that were shared with the thymus were IgGswitched compared to only 27.8% of the clones that were not shared (paired t-test
P=0.003) (fig. 4B). By comparison there was no significant difference in the fraction of
IgM or IgA-switched V(D)J sequences among clones that were shared compared to those
that were not shared.

We then tested if these IgG-switched B cell clones in the circulation, which are shared
with the thymus, have higher frequencies of SHM compared to non-shared circulating
clones, given our previous observation that IgG-switched B cells in the thymus are more
mutated. The frequency of SHM among shared clones in the circulation was 6.3% while
the frequency among non-shared IgG-switched clones was 5.1%, (paired t-test P=0.024)
(fig. 4C). No significant differences were observed in the SHM frequency of IgM and
IgA clones that were shared with thymus repertoire compared to those that were not
shared. These findings are also consistent with the possibility that B cells in the
circulation belonging to clones shared with the thymus display features specific to
thymus-resident B cells and may therefore have emigrated from the thymus.
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B cell clones populating the thymus persist in the circulation after thymectomy
We next sought to investigate the fate of circulating thymus-associated B cell clones after
thymectomy. Thus, clones shared between the thymus (at baseline) and PBMCs collected
twelve months after thymus removal were examined. A mean of 245.7 (1.0% of all
thymus clones) clones were shared between the thymus and post-thymectomy circulation
while a mean of only 65.7 (0.046% of all thymus clones) clones could be found to be
shared in the background (one-tailed paired t-test P=5.4e-4) (figs. 2B, S6). We also
investigated whether there was more sharing than expected between the thymus, prethymectomy circulation, and post-thymectomy circulation. We observed a mean of 104
(0.40% of all thymus clones) clones shared in all three compartments while only 32
(0.25% of all thymus clones) were found shared in the background (one-tailed paired ttest P=0.017) (figs. 2C, S6).

Additionally, we closely examined shared clones containing shared mutations relative to
their inferred germline sequences. Two such trees from two independent B cell clones,
members of which occupy both the thymus tissue and circulation prior to and 12-months
post thymectomy, are shown as illustrative examples (figs. S8 and S9). These clonal
variants (produced during the evolution of an immune response) are members of the same
clone and contain many shared mutations, which are highly unlikely to arise by
independent affinity maturation processes in separate tissues.
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As a means to further validate the finding that thymus-resident clones persist in the
circulation after thymectomy, we studied a patient (THY-Y) who underwent thymectomy
at a tertiary care facility unaffiliated with the MGTX trial (table 1). We tested for shared
clones between the thymus and the circulation both prior to and at six months after
thymectomy. The number of shared clones prior to thymectomy (3126 clones) and at 6
months (660 clones) was more elevated than the background at those same time points
(417.1 clones prior to thymectomy one-tail paired t-test p=5.4e-8; 118.74 clones after
thymectomy one-tail paired t-test p=3.4e-6) (figs. 5A-D). Thus, these findings provide an
independent confirmation that B cell clones populating the hyperplastic MG thymus can
persist in the circulation following thymectomy.

Finally, we investigated whether the frequency of thymus-associated clones would
decline over time as a consequence of thymectomy. The fraction of circulating thymusassociated clones (quantified in figs. 2A and 2B) pre-thymectomy and 12 months after
thymectomy was examined. Five out of seven patients showed a decline in the frequency
of thymus-associated clones in the circulation. (fig. 2D). Moreover, for the same five out
of seven patients, a similar decline was observed when investigating only the IgG
compartment (fig. 2E). Thus, for most patients, thymus-associated B cell clones can
persist at 12 months after thymus removal. However, the fraction of these circulating
clones generally declines after thymectomy although this is not consistently observed
across all patients.

Circulating thymus-associated B cell clones initially mature in the thymus.
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We next investigated whether shared clones showed evidence of movement from the
thymus to the circulation by analyzing the lineage structure of these clones. Only IgG
sequences from the thymus and circulation at the time of thymectomy were included in
this analysis because of their importance in AChR autoantibody MG immunopathology.
Given the location (thymus or circulation) associated with each tip of a lineage tree, we
used a maximum parsimony algorithm (24) to determine the most parsimonious history
of changes between thymus and circulation along the tree. The types of predicted changes
that occurred within the trees of each repertoire were then compared to those obtained
from the same trees with randomized tissue states (circulation or thymus) at the tips
(158). Two patients (THY6 and THY7) showed a significantly greater proportion of
predicted changes from thymus to circulation compared to randomized trees (both
P=0.01; table S3). Two patients (THY1 and THY2) showed a greater proportion of
changes in the opposite direction – from circulation to thymus – but these did not reach
significance (P=0.37 and 0.17, respectively). However, when analyzed as a group, the
patients had a significantly greater proportion of predicted changes from thymus to
circulation with a Fisher combined P value of 0.014. These results suggest a biased
ancestor/descendant relationship from the thymus to circulation within the lineage trees
of these patients. This relationship could theoretically be driven by under-sampling of
thymus sequences relative to circulation (158). However, between 1.9 and 260
(median=2.7) fold more sequences were obtained from the thymus than circulation for
the patients included (table S3). This suggests under-sampling of the thymus is unlikely.
Rather, we reason that, after switching to IgG, these clones accumulated early somatic
hypermutations in the thymus before migrating to circulation.
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Changes in the frequency of shared B cell clones correlates with measures of clinical
outcome
Associations between features of the B cell repertoire and clinical measurements were
next explored. We specifically tested whether the change in the sharing of clones between
the circulation and thymus correlated with clinical benefit from thymectomy by
comparing the change in clonal sharing with measures of patient outcome available from
the MGTX clinical trial (27). The primary outcomes of change in average Quantitative
MG (QMG) test score and change in average steroid dosage (in mg) were examined.
Given that two patients were not treated with daily prednisone prior to the start of the trial
(subjects THY3 and THY5, Table1), only the change in steroid dosage between years 1
and 2 (after concomitant steroid treatment has been started after thymectomy) could be
examined. By comparison, the change in QMG score between baseline and year 1, and
between year 1 and year 2 were both examined. To account for the different depths of
sequencing from the blood and thymus samples, a Bray-Curtis index for sharing, which
quantifies the number of clones shared between these two compartments as a fraction of
the combined size of the two compartments, was computed. A Bray-Curtis index of 1
indicates that two sites share all the same clones; an index of 0 indicates that no clones
are shared. To express relative changes in sharing between the thymus and circulation,
the (log) fold change (comparing baseline and post-thymectomy) in Bray-Curtis index
between the two compartments was computed.
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The association between change in total sharing with the change in QMG score was
examined first. A significant positive correlation of 0.727 was observed (P=0.032)
showing that increased clonal sharing between 0 and 12 months is associated with
increases in QMG score and therefore a worsening clinical outcome while decreased
clonal sharing is associated with decreased QMG score and better clinical outcomes (fig.
6A). However, no correlation was found between the change in QMG score between
baseline (pre-thymectomy) and year one with the change in clonal sharing (-0.024,
P=0.521) (fig. 6B). Next, the change in total clonal sharing with the change in
prednisone dose was quantified between years 1 and 2. A significant correlation of 0.874
was observed (P=0.005) showing that increases in clonal sharing are associated with
increases in steroid requirements needed to control symptoms (fig. 6C). Similar
associations were detected when restricting the analysis to IgG-switched B cell clonal
sharing and clinical outcomes with a significant correlation observed between change in
sharing and change in QMG score between year one and two (0.855, P=0.007) (fig. 6E)
but not between baseline and year one (0.378, P=0.15) (fig. 6F); significant correlations
were also observed for change in sharing and change in prednisone dose (0.688, P=0.044)
(fig. 6G). Overall, patients from the trial who had fewer thymus B cell clones shared with
the circulation after thymectomy had more favorable outcomes than those who had more
thymus clones after thymectomy. The is well-illustrated by the findings derived from
patient THY1, who responded poorly to thymectomy with an increase in QMG score
between year 1 and 2 (+0.472, and also little change between baseline and year 1 -2.877)
and only a 10.6 mg decline in steroid dose. This patient also had only a slight decrease in
the sharing between clones from the resected thymus (log fold decrease of -0.08, or a
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decrease of 7.7%) and the circulating repertoire. By comparison, both patient THY6 and
THY7 performed well in terms of change in QMG score (-0.917 and -1.093 respectively)
and steroid dosage (-21.2 mg and -18.6 mg respectively). These patients had decreases in
clonal sharing between the circulation and the thymus after thymectomy (log fold change
of -2.031 or 86.9% and -2.753 or 93.6% respectively). Thus, smaller decreases (or even
no decrease) in clonal sharing between the circulation and thymus may be associated with
poor outcomes in terms of long-term changes in steroid dose and QMG score between
years 1 and 2 but not between baseline and year 1, that is, immediately after surgery.

Associations with AChR autoantibody titer were available for six patients. The change in
clonal sharing was compared to the percent change in AChR autoantibody titer between
year 1 and 2, as the change in clonal sharing was also observed to correlate with change
in QMG and steroid use during this time period. A significant correlation was observed
when examining the total immunoglobulin repertoire (P=0.037, Figure 6D) however no
significant correlation was observed when examining the IgG-switched repertoire
(P=0.077, Figure 6H). To test if the persistence of clonal overlap would also depend on
the accumulation of disease-relevant thymus B cells over time, the correlation between
duration of disease prior to thymectomy and the persistence of these B cells was also
examined. No significant correlations were observed with change in total
immunoglobulin or IgG overlap (Figure S10A, B). Thus, thymic B cell persistence may
directly contribute to changes in elevated AChR autoantibody titers after thymectomy in
some patients. However, this association is less clear than the direct correlation between
persistence and symptoms.
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Discussion
Thymectomy was recently confirmed to be beneficial in a randomized clinical trial
setting (22, 27, 28). While patients often improve following thymectomy, complete stable
remission is seldom achieved with surgery alone. The thymus is also a source of diseasecausing AChR autoantibody-producing B cells. In this study, we test the hypothesis that
circulating B cell clones can be traced to thymus B cell clones, including plasma cells,
and that the persistence of these clones is associated with poor disease outcomes. By
testing this hypothesis, which has not been previously investigated, we can potentially
show that B cell clones in the periphery of patients with AChR-MG persist and could
contribute to poor disease outcomes. We formally tested this hypothetical model by
applying adaptive immune receptor repertoire (AIRR) sequencing approaches, which can
identify rare disease-related sequences in the large (1011 B cells) circulating peripheral B
cell gene repertoire found in humans (159). By broadly sequencing the B cell receptors of
thymus B cells, we found that (1) thymus-associated B cell clones persist in the
circulation long after thymectomy, which was demonstrated using two complementary
approaches and independent sets of samples; (2) shared clones (those found in both the
circulation and thymus) were IgG-switched, displayed a high frequency of accumulated
SHM, including those generating N-glycosylation sites, all of which are features
consistent with an antigen-driven response; (3) clonal family trees showed that a
disproportionate frequency of these clones originated from the thymus, suggesting that
they accumulated mutations in the thymus before migrating to the circulation and; (4) an
increased frequency of persistent clones showed a positive association with a worse
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disease status after the treatment, and (5) was associated with changes in AChR
autoantibody titers in some patients. These findings provide key insights into the
mechanisms of MG immunopathology and the association between residual thymusassociated B cell populations and poor outcomes after thymectomy.

We employed a number of steps to ensure rigorous data collection. First, we used both
genomic DNA and RNA for the sequencing template. DNA and RNA were isolated from
whole blood as part of the MGTX trial. These specimens were collected and processed at
a site separate from our laboratory. Furthermore, the DNA-based and RNA-based
sequencing were performed at separate sites. DNA specimens were sent to a commercial
sequencing organization. Raw sequencing data was returned and analyzed by us. RNA
specimens were sequenced and analyzed in-house. Finally, we studied a thymus
specimen and matched PBMCs (time 0 and 6 month) collected at an institution outside
the MGTX trial, and the analysis of these specimens was completely independent of
those from the trial. The collective data derived from these independent specimens and
multiple approaches all provide results consistent with each other, and consistent with
overall interpretations regarding persistent B cell clones post-thymectomy.

Our findings suggest that B cell clones frequently accumulate ancestral mutations in the
thymus before emigrating to the periphery. This indicates that the thymus may be the site
in which these autoreactive B cells originate and mature. Their origin in the thymus is
supported by a number of studies that highlight MG thymus resident cell populations as
essential for the initiation and maintenance of autoantibody production. The MG thymus
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includes myoid cells that express AChR (144) and proinflammatory cytokines. Moreover,
MHC class I+ and class II+ medullary thymic epithelial cells (mTEC) express AChR
subunits (160) and are recognized by both autoantibodies (161) and complement (162) in
the thymus. These mTECs play a role in priming and activating AChR-specific T cells.
These T cell subsets include thymic-resident regulatory T cells (Tregs) that are defective
in their ability to control autoimmune responses (163, 164) and importantly CD4+ helper
T cells that could activate antigen-specific B cells (19). Together, these T cell populations
are key components of germinal centers that produce mature AChR-specific B cells and
defective Tregs that contribute to perpetuating an abnormal response. Removal of the
thymus would also remove these disease-relevant non-B cell subsets. Given their
fundamental role in the autoimmune response, the diminished presence of these cell
subsets is likely to also play a role in disease outcome following resection.

Exploratory examinations of potential clinical correlates were performed to broadly
determine whether the frequency of circulating thymus-associated B cell clones
associated with disease severity and treatment outcome. We observed an association
between the steroid dose that was required to control disease and the change in clonal
sharing of thymus-associated B cell clones for patients involved in the MGTX two-year
extension. This longer-term observational period was required to reach statistical
significance. This finding supports the hypothesis that thymectomy reduces the frequency
of circulating thymus-associated clones and that this beneficial effect may require
considerable time to manifest. This is congruent with other studies that suggest that the
thymus is the origin of autoantibody-producing clones, and serves to maintain these
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subsets during the course of disease (143, 165, 166). However, poor correlation between
the change in clonal sharing and the change in QMG score was observed over the first
year. We speculate that this reflects the possibility that the persistence of thymus B cells
and plasma cells does not correlate with immediate treatment response after the surgery,
but rather with more long-term outcomes. We also caution against interpreting changes in
the persistence of thymus B cells in the circulation for the patient unaffiliated with the
MGTX trial. The time after thymectomy when clonal overlap was assessed was shorter (6
months) for this patient compared to the trial (12 months) and it is not clear if changes in
overlap are interpretable at this time point. Finally, no correlation was observed with
change in clonal overlap and disease duration prior to thymectomy. This suggests that the
accumulation of AChR autoantibody-specific B cells in the thymus may not be directly
associated with duration of disease prior to thymectomy.

With new details provided by this study, we propose an updated speculative mechanism
describing the immunopathology of AChR autoantibody positive MG involving thymic
lymphofollicular hyperplasia. Immune dysregulation, a hallmark of autoimmunity, occurs
during B cell development. B cells, developing in the bone marrow, include an elevated
fraction of self-reactive cells due to B cell tolerance checkpoints, which are known to be
defective in MG (167). This population of naïve B cells, which avoided counterselection,
has been shown to serve as precursors to mature autoreactive B cells in other autoimmune
settings and may play a similar role in MG (168). These naïve B cells encounter AChR
antigen(s) in the thymus presented by TECs and also receive T cell help; they then
differentiate into memory B cells and autoantibody-secreting cells. These autoreactive B
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cell populations can remain in the thymus, most likely as residents of structures that
resemble germinal centers that are characteristic of thymic lymphoid hyperplasia. These
B cells then migrate from the thymus and populate other compartments. Clonal relatives
of thymic emigrants, as shown here, can be found in the circulation. In addition, AChR
autoantibody producing cells are known to populate peripheral tissue compartments;
specifically, they have been found in the circulation, lymph nodes and in the bone
marrow (19, 29–31, 141). While thymectomy will remove a large fraction of thymusresident autoreactive B cells, plasma cells and the cells that support their development,
this treatment is performed only once the disease is established. This may be too late to
halt disease progression, as those thymic B cells which have emigrated contribute to
ongoing disease.

Our study included patients with extensive clinical documentation given their enrollment
in the MGTX trial. However, we recognize the limited number of patients included in the
present study and thus encourage caution in generalizing our findings. The investigation
nevertheless provides further support for the benefits of thymectomy and provide new
details regarding the mechanism of the disease immunopathology. The clinical
correlations should be explored in larger studies. We did not observe persistent thymusassociated clones in all of the patients studied. This, in our view, could be attributed to
limited sequencing depth in some of the specimens. We find that thorough
characterization of the circulating repertoire requires sequencing unmanipulated PBMCs
in the 1– 4 x 107 total cell range; specimens of such size were not available from the
MGTX trial (99). This point is highlighted by the study of the sample that was collected
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at our institution from which we acquired remarkable sequencing depth from a large
number of PBMCs. However, we leave open the possibility that in a subset of patients,
thymus resident B cell clones do not reside outside of that tissue and/or do not persist in
the circulation following surgical resection.

While our study leveraged a well-established computational platform for the
identification of B cell clones from AIRR-Seq data, precise identification of clones is not
without limitations. Identifying clones in separate tissues can be confounded by errors
associated with misidentification of similar sequences that arise out of V(D)J
recombination generated with similar (or identical) IGH gene segments. Clonal
relationships can be reliably inferred from IGH V(D)J sequences based on our previous
studies but this is a statistical procedure and false positive relationships do occur (56).

Questions remain concerning post thymectomy therapeutic strategies and thymic-resident
B cell phenotypes. While thymectomy removes a source of autoantibody-producing B
cells, those that have emigrated from the thymus may continue to contribute to disease,
particularly those that have already fully differentiated into plasma cells. This is
supported by evidence from investigations of plasma cells from non-thymus sources such
as the bone marrow in patients with AChR-MG (30, 31). Combination therapies aimed at
targeting residual thymus-associated B cells may prove to be a valuable part of a potential
therapeutic strategy. The use of B cell depleting agents, such as rituximab—which is
currently used for the treatment of MG—fits this approach well(4–6). Nevertheless,
several groups have shown that patients with a different subtype of MG (MuSK) lacking
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thymic abnormalities respond more consistently to B cell depletion therapy with
rituximab than patients with AChR-MG, consistent with the resistance of diseasecausing, tissue-resident, plasma cell-like B cell subsets (lacking surface CD20) in AChRMG compared to MuSK MG (4–6). Thus, consideration may also be given to anti-CD19
based treatments that would specifically target plasma cells thought to be spared by
rituximab (169). AIRR-Seq approaches employed in this study do not distinguish plasma
cells from B cells; the relative importance of these two subsets is unclear. While thymic
plasma cells spontaneously produce AChR autoantibodies, their CD20+ germinal center
B cell counterparts also possess AChR reactivity and the frequency of germinal centers
associates with disease severity and AChR autoantibody titer (32, 139, 145). Thus,
although plasma cells are known to play an important role in the etiology of AChR-MG
through the production of AChR autoantibodies, CD20+ B cells also appear to make
contributions to disease pathogenesis.

Combining our approach with single-cell transcriptome and simultaneous paired
repertoire techniques would afford the characterization of the transcriptomes of these B
cell populations. These studies would also afford the production and testing of
recombinant monoclonal antibodies for AChR binding and pathogenic capacity from
thymus-associated B cells. Additionally, thymus B cells are not all AChR-specific (141,
146). The B cell receptors we found in the thymus were nearly 100% antigen experienced
and are likely to also target exogenous (e.g. infection or vaccination related) and perhaps
self-antigens (141, 170). Provided these disease-relevant cells had unique and identifiable
transcriptional characteristics, they could also serve as valuable biomarkers for
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monitoring MG disease progress. Diagnostic algorithms incorporating thymus imaging
after thymectomy and/or BCR repertoire evaluation may provide a means to assess the
potential need for surgical re-exploration versus further immunotherapy. Thus, tracking
the persistence of thymic-derived B cells after therapy may represent an invaluable
biomarker for the management of patients with AChR-MG.

Materials and Methods
Study Design
Subjects were selected at random from the total of 82 MGTX subjects who completed the
trial and provided biological samples. Subjects without adequate thymic tissue or whole
blood DNA/RNA samples for analysis were excluded, then substitutes were randomly
selected. An additional thymus specimen and matched PBMCs were collected from a
patient who underwent thymectomy at Yale New Haven Hospital and was treated at the
Yale Myasthenia Gravis Clinic. This patient and these specimens were not affiliated with
the MGTX trial. Clinical and demographic information for the entire study cohort are
provided (table 1).

Radioimmunoprecipitation assay for AChR autoantibody levels
AChR autoantibody levels for the MGTX trial specimens were measured by
radioimmunoprecipitation assay (RSR Ltd, UK) (151). A serum concentration was
chosen for each patient baseline sample which immunoprecipitated approximately 4050% of the total, and that concentration was used for each of the samples from that
patient. Titers were expressed as nanomoles precipitated by a liter of serum. For
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assessing changes over time, the percent change in titer for each patient was used rather
than the actual titer. The AChR autoantibody levels for specimens from patient THY-Y
were measured by radioimmunoprecipitation assay performed at the Mayo Clinical
Laboratories, (Rochester, MN USA), using a reference range positive > 0.02 nmol/L.

Isolation of thymus gDNA and RNA for AIRR sequencing
Thymus regions were selected for sequencing based on the presence of B cell-enriched
germinal center-like structures, the presence of which was confirmed through tissue
section histology and immunohistochemistry. Thymus blocks from the MGTX trial were
mounted and frozen in OCT. Sections were then isolated and assessed for the presence of
such structures by staining with hematoxylin and eosin (H&E) and a mouse anti-human
CD23 antibody (clone M-L233, BD Pharmingen catalog number 555707), as per the
manufacturer’s instructions. Once a region was confirmed to include a B cell-enriched
germinal center-like structure, adjacent tissue slices were collected and immediately
placed in RLT lysis buffer for RNA extraction using the Qiagen RNA Mini kit per
manufacturer’s instructions. For mRNA-based sequencing, approximately ten contiguous
10-micron slices were extracted from each block. Genomic DNA (gDNA) was isolated in
a similar manner, except that sections were immediately placed in lysis buffer using
QIAgen's DNAeasy Blood and Tissue kit per the manufacturer’s instructions. For the
patient not associated with the MGTX trial, sections were collected and mRNA was
isolated for sequencing using methods similar to those described for MGTX specimens,
except only H&E staining was performed to confirm the presence of a lymphocytic
infiltrate. In addition, adjacent, formalin fixed paraffin embedded thymus blocks, from
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this patient, were available. Sections were stained with an anti-CD20 monoclonal
antibody (clone L26, Dako/Agilent catalog number M0755), as per the manufacturer’s
instructions.

BCR library preparation
For gDNA-derived BCR libraries, BCR CDR3 regions were amplified and sequenced
using the ImmunoSeq assay which involves a multiplexed PCR using forward primers
specific to VH gene segments (located in the FR3 region) and reverse primers specific to
the BCR JH gene segments (Adaptive Biotechnologies). RNA-derived BCR libraries
were prepared using the NEBNext Immune Sequencing Kit (Human) reagents provided
by New England Biolabs (Drs. Eileen Dimalanta and Chen Song, Ipswich,
Massachusetts). The RNA was reverse-transcribed into cDNA using a biotinylated oligo
dT primer. An adaptor sequence, containing a universal priming site and a 17-nucleotide
unique molecular identifier (UMI) was added to the 3’ end of all cDNA. Following
purification using streptavidin-coated magnetic beads, PCR was performed to enrich for
immunoglobulin sequences using a pool of primers targeting the IGHA, IGHD, IGHE,
IGHG, IGHM, IGKC and IGLC regions. This immunoglobin-specific primer pool
contained sequences with a priming site for a secondary PCR step. The second primer in
this reaction is specific to the adaptor sequence added during the RT step, and contains a
sample index for downstream pooling of samples prior to sequencing. Following
purification of PCR products using AMPure XP beads, a secondary PCR was performed
in order to add the full-length Illumina P5 Adaptor sequence to the end of each
immunoglobin amplicon. The number of secondary PCR cycles was tailored to each
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sample to avoid entering plateau phase, as judged by a prior quantitative PCR analysis.
Final products were purified, quantified with a TapeStation (Agilent Genomics) and
pooled in equimolar proportions, followed by sequencing with a 20% PhiX spike on the
Illumina MiSeq platform according to manufacturer’s recommendations, performing 325
cycles for read 1 and 275 cycles for read 2.

Raw read quality control and assembly
Preprocessing was carried out using pRESTO v0.5.4 (http://presto.readthedocs.io). Reads
below a mean phred score of 20 and those without a constant region primer (above error
rate of 0.2) or template switch sequence (above error rate of 0.5) were discarded. A UMI
was assigned to each read by extracting the first 17 nucleotides following the template
switch site. Multiple reads from the same UMI were aligned using MUSCLE v3.8.31
(171). Sequencing and multiplexing errors in the UMI region were then corrected using
the following approach. Sequences with similar UMIs were clustered using the CD-HITEST algorithm v4.7 (172) by analyzing the distribution of pairwise sequence hamming
distances; 10,000 UMI sequences were sampled and the threshold was identified as the
minima between 1.0 (identical) and 0.25 (the expected hamming distance between two
random sequences of 4 nucleotides). These groups of sequences were further clustered
into smaller groups; the average distribution of pairwise sequence hamming distances
across the non-UMI region of the sequence was computed for all groups. Sequences were
then clustered using a threshold identified by an approach similar to that described above.
If clusters of sequences spanned multiple multiplexed samples, they were assigned to the
majority sample. Note that given limitations to the CD-HIT-EST algorithm, a threshold
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of 0.8 was used if the identified threshold was lower than 0.8. Reads from the same
cluster were collapsed into a consensus sequence. Clusters with errors exceeding 0.1 or
majority isotype that was less than 60% of the cluster were discarded. Mate-pairs were
assembled into immunoglobulin sequences with a minimum overlap of 8 base pairs and
maximum error of 0.3. Mate-pairs failing this assembly were assembled by alignment
against the IMGT human germline IGHV reference database (IMGT/GENE-DB v3.1.19;
retrieved June 21, 2018) with a minimum allowed identity of 0.5 and a E-value threshold
of 1x10-5 (173). Isotypes were assigned by local alignment of the 3’ end of assembled Ig
sequences to known isotype constant region sequences with a maximum tolerated
mismatch of 0.4. Duplicate sequences were discarded except those assigned to different
isotypes. Sequences represented by only a single reconstructed mate-pair sequence were
discarded.

V(D)J gene annotation, sequence filtering, clonal assignment and germline
reconstruction
Following preprocessing, V(D)J germline genes were assigned with IgBLAST v1.7.0
(103) using the June 21, 2018 version of the IMGT gene database. Following V(D)J
annotation, non-functional sequences were removed. Functional VH V(D)J sequences
were assigned into clonal groups using Change-O v0.3.4 (56). First, sequences were
partitioned based on common IGHV gene annotations, IGHJ gene annotations, and
junction lengths. In the case of genomic DNA derived sequences, primer annotations
were used to assign IGHV and IGHJ gene annotations. Within these larger groups,
sequences differing from one another by a length normalized Hamming distance within
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the junction region were defined as clones by single-linkage clustering. The clonal
distance threshold was determined by identifying the local minima between the two
modes of a within-sample bimodal distance-to-nearest histogram (56); the final threshold
chosen was the average threshold across all samples. Clones from these V(D)J sequences
were identified by grouping sequences using identical VH and JH genes with a fraction of
shared junctional nucleotides less than a specified (7.7% for genomic DNA, 18.8% for
RNA sequencing) threshold (fig. S5, S7). Full length germline sequences were
reconstructed for each clonal cluster (VH) or sequence (VL) with D segment and N/P
regions masked (replaced with Ns); any ambiguous gene assignments within clonal
groups were resolved by majority rule.

Analysis of somatic hypermutation (SHM), selection pressure, lineage trees, diversity and
CDR3 properties
Mutations were detected relative to the germline sequence using SHazaM v0.1.8 in R
v3.4.2 (107). A minimum threshold of six sequences associated with a sample was used
to exclude comparisons of somatic hypermutation (SHM) involving samples with too few
sequences. Selection strength of FWR and CDR regions was quantified using the
BASELINe implementation in SHazaM (174). Analysis of CDR3 physiochemical
properties was performed using Alakazam v0.2.11. Glycosylation sites were assessed by
searching the translated VH gene after alignment (or germline re-assembly) according to
IMGT definitions for the regular expression pattern “N[^P][S,T]”. Diversity analysis was
performed using a generalized Hill index in Alakazam, with down-sampling (the number
of sequences from the sample with the fewest sequences) and bootstrapping (1,000
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replicates) from the inferred complete clonal abundance to account for variability in
depth across samples (108). Clonal sharing was computed using a Bray-Curtis metric
implemented by the function scipy.spatial.distance.braycurtis (scipy v1.1.0) and log
transformed for assessing background significance. In this analysis, the average overlap
in comparisons with the circulating repertoire of other subjects from the trial was
computed (the background, “inter-patient”) relative to the overlap between the circulating
and thymus repertoire from the same individual (“intra-patient”). The analysis of shared
clones in the thymus and circulation was restricted to thymus samples with more than
5,100 isotype-switched V(D)J sequences given the importance of consistent sequencing
depth for the identification of sharing and quantification of significance.

Inference of B cell lineage trees and migration analysis
The goal of these analyses is to use B cell lineage trees to determine whether IgG
sequences in the thymus were predicted to be the immediate ancestor to IgG sequences in
the blood more frequently than expected by chance. To account for uncertainty in tree
topology, the columns of each clone’s multiple sequence alignment were sampled with
replacement, forming bootstrap replicates. B cell lineage tree topologies and branch
lengths were then estimated for each replicate using the dnapars program distributed as
part of PHYLIP (v3.697) (110). An implementation of the Sankoff parsimony algorithm
(111) with equal weights for switches among locations was then used to determine the set
of internal node locations that resulted in the fewest number of location changes along the
tree, given the sampling location of each sequence at the tree’s tips. Clusters of internal
nodes separated by zero length branches (polytomies), were re-ordered using nearest-
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neighbor interchange (NNI) moves to minimize the number of changes along the tree and
to appropriately represent possible directions of migration (158). For each bootstrap
replicate, the proportion of predicted changes from the thymus to the circulation (switch
proportion; SP) was compared to the same statistic in trees where sample locations were
randomized at the tips. The difference between these values (𝛿) was recorded, and this
process was repeated for 1000 bootstrap replicates. The P value for enrichment of
changes from thymus to circulation (i.e. 𝛿 > 0) is the proportion of replicates in which 𝛿 ≤
0. If P < 0.05 and 𝛿 > 0, this indicates a significantly more biased ancestor/descendant
relationship from thymus to circulation IgG than expected by chance in the lineages
surveyed. Only IgG sequences were included. Further, only clones that contained at least
one sequence from the thymus and circulation at the date of thymectomy and contained
more than two sequences that were either distinct or found in different samples, were
included. Clones found to be erroneous because they spanned multiple patients were
excluded. Patients THY3, THY4, and THY8 had fewer than two clones each satisfying
these criteria and were therefore not included in this analysis. These analyses were
performed using the R package dowser v0.0.1 (Hoehn et al. 2020) and IgPhyML v1.1.3
(112).

Statistical analysis
R v3.4.2 (107) and Python v3.5.4 was used for all statistical analysis. Dataframe handling
and plotting was performed using functions from the tidyverse v1.2.1 in R and pandas
v0.24.2, scipy v1.1.0 and matplotlib v2.2.2 in python3. All parametric statistical testing
was performed in R using the aov function for two-way ANOVA or t.test functions for
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paired two-tailed student t-tests (or one-tailed student t-test where specified). A
significance threshold of <0.05 was used and shown on plots with a single asterisk;
double asterisks correspond to a p <0.01 and triple asterisks correspond to a p<0.001.

Data and materials availability: Bulk repertoire V(D)J data are submitted to NCBI
(BioProject ID: PRJNA658100). Code used in this study will be made available in a
publicly accessible repository (https://bitbucket.org/kleinstein/projects).
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Tables
PATIENT
ID,
GENDER,
AGE

MGFA
CLASS
AT TX

DISEASE
DURATIO
N AT TX
(YEARS)

PREDNISONE
AT TX (mg/day)

PREDNISONE
1 YEAR AVG
(mg/day)

PREDNISONE
2 YEAR AVG
(mg/day)

AChRAb AT
TX

AChRAb AT
1
YEAR

AChRAb AT
2
YEAR

THY1 F, 20

IIb

2.4

40

49.2

38.6

41.14

51.28

62.10

THY2, F 19

III

0.4

10

45.4

34.4

31.60

27.996

29.70

THY3, F, 19

IIb

0.6

0

36.6

17.6

36.36

28.24

26.61

THY4, F, 18

IIa

1.9

30

48.5

35.1

12.66

15.636

13.35

THY5, F, 46

IIa

0.9

0

35.9

35.9

112.60

36.08

43.24

THY6, M, 24

IIb

1.1

50

61.9

40.7

28.57

29.864

23.70

THY7, F, 22

IIa

0.7

25

37.1

18.5

No data

No data

No data

THY8, F, 21

III

0.7

38

THY-Y, F,
36

IIb

2.8

20

327.64
nonMGTX

60.9

32.3

165

367.76

non-MGTX

non-MGTX

0.22

0.25*

Table 1. Demographic and clinical information of study patients at the time of
thymectomy. TX=Thymectomy. AChR-Ab titers are given in nanomolar units (nM).
*AChR antibody titers for patient outside MGTX trial were collected at baseline at 6
months after thymectomy.
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Figure 1. The thymus-associated B cell repertoire is distinct from the paired circulating
repertoire. AIRR sequencing was performed to generate B cell repertoires for eight
MGTX trial-derived thymus specimens and paired PBMCs collected at baseline. Key
features of antigen-experience B cells in each of the respective repertoires were then
compared. (A) Overall constant region (isotype) usage frequencies are quantified for
thymus compared to the circulating compartment per patient. Horizontal bars show the
average frequency of constant region usage across patients. Frequencies belonging to the
same patient are paired with a black line. (B) Individual SHM frequencies for thymus
compared to circulating B cells are presented. Horizontal bars show the average somatic
hypermutation frequency for a given sample status i.e. thymus or circulation. Frequencies
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belonging to the same patient are paired with a black line. (C) BASELINe probability
distribution functions (PDF) are shown for thymus and circulating repertoires, with
density shown for a range of selection strengths (∑) on the x-axis. PDFs were determined
via convolution of subject-specific PDFs for each status to generate a single aggregate
status. (D) Individual frequencies for the occurrence of glycosylation (N[X][S/T]) sites
are quantified for thymus compared to circulating B cells and (E) for the inferred
germline of these sequences. Horizontal bars show the average glycosylation frequency
for a given cluster. Frequencies belonging to the same patient are paired with a black line.
Statistical differences are shown only when significant (****P < 0.0001; ***P < 0.001;
**P < 0.01; *P<0.05).
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Figure 2. B cell clones are shared between thymus and circulation before and 12 months
after thymectomy. An mRNA-based sequencing approach was used to evaluate how B
cells clones are shared between the thymus and circulation before and 12 months after
thymectomy. The schematic diagram shows the corresponding computation of clonal
sharing associated with each subpanel below. Clonal sharing is quantified as the number
of shared clones divided by the number of clones in the corresponding thymus repertoire
(or background thymus repertoire). This is shown for the sharing of clones found in the
thymus with (A) clones found in pre-thymectomy circulation, (B) the post-thymectomy
circulation samples and also (C) clones shared between the pre and post-thymectomy
circulation samples. The change in sharing per patient is also shown before and after
thymectomy (D) for both the total repertoire and (E) for the repertoire filtered only for
IgG-switched V(D)J sequences. Quantification of clonal sharing from the same patient is
paired with a gray line. Statistical differences are shown only when significant (****P <
0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure 3. B cell clones are shared between thymus and circulation before a thymectomy.
A genomic DNA-based sequencing approach was used to confirm that B cells clones are
shared between the thymus and circulation before thymectomy. The observed number of
shared clones is shown for patient THY6 (A), patient THY7 (B) and patient THY2 (C).
The computed background sharing is shown as Venn-diagrams for THY6 (D), patient
THY7 (E) and patient THY2 (F). Background sharing was computed by changing the
identity of the thymus used to assess for clonal sharing, that is, the observed sharing of
clones from thymus samples derived from different patients with the circulation and
computing an average. Uncertainty was computed as the standard deviation of values
from the corresponding background sharing and are shown in (D-F) using the ± symbol.
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Figure. 4. Features of clones shared between the thymus and pre-thymectomy circulation
are distinct from circulating clones that are not shared. (A) Simpson’s diversity of shared
pre-thymectomy and thymus clones in the circulation. Lower values of diversity
correspond to greater clonal expansion, that is, circulating clones shared with the thymus
are more clonally expanded than their non-shared circulating counterparts. Diversity
values belonging to the same patient are paired with a gray line. (B) Usage of different
isotypes among shared and non-shared clones is shown for IgM, IgG and IgA for the
circulating repertoire. Horizontal bars show the average isotype usage frequency for
clones that are either shared or not shared. Frequencies belonging to the same patient are
paired with a gray line. (C) Average SHM frequencies among shared and non-shared
clones are shown for IgM, IgG and IgA for the circulating repertoire. Horizontal bars
show the average somatic hypermutation frequency for a given cluster. Frequencies
belonging to the same patient are paired with a gray line. Statistical differences are shown
only when significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure. 5. Confirmation of B cell clonal sharing with the circulation in specimens (THYY) independent of the MGTX trial. (A) Observed number of clones shared between the
pre-thymectomy, post-thymectomy circulation and thymus shown as Venn diagrams. (B)
Computed background sharing between the pre-thymectomy, post-thymectomy
circulation and thymus are shown as Venn diagrams. Background sharing was computed
by permuting the identity of the thymus used to assess for clonal sharing and computing
an average; this approach is identical to the approach used to compute clonal sharing for
thymus samples from the MGTX trial. Uncertainty was computed as the standard
deviation of the background clonal sharing and shown using the ± symbol. Statistical
testing of observed counts of shared clones between circulation and thymus repertoire (C)
pre-thymectomy and (D) post-thymectomy. Statistical differences are shown only when
significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).

113

Figure 6. Correlation between clinical outcome measurements and circulating thymusassociated B cells. Correlation of the log fold change in clonal sharing between the
thymus and circulation as assessed with a Bray Curtis index (on the x-axis) and with (A)
the change in QMG score between year 1 and 2 after thymectomy, (B) the change in
QMG score between baseline and year 1 after thymectomy, (C) the change in steroid
dose between year 1 and 2 after thymectomy and (D) the percentage change in AChR
autoantibody titer between year 1 and 2 after thymectomy (on the y-axis). The same
analysis is shown for the log fold change in IgG clonal sharing (E-H) respectively. AChR
autoantibody titer was not collected for THY7 (D) and (H).
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Supplemental Information

Figure S1. Histology section showing multiple germinal centers (arrows) in a frozen
section from thymus (specimen from patient THY2). Specimen stained with H&E (A, B).
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A

B

Figure S2. Identification of a B cell infiltrate in specimen THY-Y; a sample from a
patient who was not associated with the MGTX trial. (A, B) CD20 staining is shown
showing cortex with B cell infiltration of the medulla (arrows).
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Figure S3. Experimental outline illustrating the three approaches used to investigate the
presence of clonal overlap between the thymus and the circulation. The goal of the first
approach was to identify overlap between the circulation and the thymus before and after
thymectomy in MGTX samples and characterize the features of that overlap. This was
performed using an RNA-based B cell receptor AIRR-Seq approach. The goal of the
second approach was to confirm the presence of overlap between the circulation and the
thymus before thymectomy using gDNA-based B cell receptor AIRR-Seq. The goal of
the final approach was to confirm the presence of overlap between the circulation and the
thymus before and after thymectomy in a sample from an independent patient sample
collected at a different institution.
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PATIENT

TIME

CLONES

IgA V(D)J
SEQUENCES

IgG V(D)J
SEQUENCES

IgM V(D)J
SEQUENCES

THY1

0 Months

4967

1740

1317

3391

THY1

12 Months

3978

918

737

2941

THY1

Thymus

12418

1616

16225

689

THY2

0 Months

20756

6982

7518

13879

THY2

12 Months

7997

4959

4505

4649

THY2

Thymus

38252

7735

58372

9753

THY3

0 Months

105

41

50

46

THY3

12 Months

90

37

35

47

THY3

Thymus

29693

4309

59637

8762

THY4

0 Months

130

110

57

18

THY4

12 Months

157

142

54

44

THY4

Thymus

3440

485

4520

274

THY5

0 Months

48

49

15

21

THY5

12 Months

305

194

108

108

THY5

Thymus

13303

2299

25397

3831

THY6

0 Months

7866

4437

1661

4921

THY6

12 Months

4684

5236

1443

1560

THY6

Thymus

11827

2226

20058

1256

THY7

0 Months

342

97

181

95

THY7

12 Months

257

86

54

130

THY7

Thymus

13885

1152

20230

924

THY8

0 Months

63

37

26

29

THY8

12 Months

114

87

24

34

THY8

Thymus

3704

182

4778

87

THY-Y

0 Months

42041

40447

13407

33711

THY-Y

6 Months

7230

3997

2239

2313

THY-Y

Thymus

38541

14547

41682

11373

Table S1. Table of V(D)J sequence counts and numbers of clones identified from mRNAbased AIRR sequencing of the B cell receptor.
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Figure S4. Thymus IgG-expressing B cells are distinct from those in paired circulating
peripheral blood. (A) VH family usage differences of circulating repertoires prethymectomy and in the thymus for IgG-switched V(D)J sequences. (B) Differences in the
usage of VH1-69 and VH3-23 gene segments of circulating repertoires pre-thymectomy
and in the thymus for IgG-switched V(D)J sequences. (C) Differences in the use of JH
gene segments of circulating repertoires pre-thymectomy and in the thymus for IgGswitched V(D)J sequences. Gene segment usage was only computed for VH family, VH
gene segments and JH genes with more than three V(D)J sequences. Horizontal bars
show the average gene usage frequency for a given cluster. Frequencies belonging to the
same patient are paired with a black line. (D) The clonal distribution of pre-thymectomy
and thymus IgG-switched V(D)J sequences is presented as diversity values using a Hill
diversity index at q=2 corresponding to the numbers equivalent of Simpson’s diversity.
Horizontal bars show the average diversity for a given cluster. Frequencies belonging to
the same patient are paired with a black line. Statistical differences are shown only when
significant (****P < 0.0001; ***P < 0.001; **P < 0.01; *P<0.05).
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Figure S5. Distance-to-nearest plots used to identify threshold for identifying clonal
members from mRNA-based AIRR-Seq of the B cell receptor. The graphs show the
distribution of junctional distance-to-nearest distances among sequences using the same
V gene and J gene with the same junction length. The minimum between the two modes
of this histogram is used to identify the threshold for assigning clusters of sequences as
clones. Upper histograms within each plot represent within patient nearest-neighbor
hamming distances, while lower histograms within each plot represent between patient
distances (which are used to identify the expected distribution of junctional distance-to120

nearest distances for sequences that do not belong to clones). The dashed vertical red line
indicates the threshold used for clonal clustering.

Figure S6. Quantification of shared clones between the thymus, pre-thymectomy and postthymectomy circulation. Venn-diagrams of shared clones between the thymus, prethymectomy and post-thymectomy circulation V(D)J repertoires for patient (A) THY1, (B)
THY2, (C) THY3, (D) THY4, (E), THY5, (F) THY6, and (G) THY7. The quantification of
observed clonal sharing is shown on the left and corresponding quantification of background
clonal sharing is shown to the right. Background sharing was computed by permuting the
identity of the thymus used to assess for clonal sharing, that is, the observed clonal sharing of
clones from thymus samples derived from different patients with the circulation was
calculated. Uncertainty was computed as the standard deviation of values from the
corresponding background overlap and is shown using the ± symbol.
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PATIENT

TIME

V(D)J SEQUENCES

CLONES

THY6

0 Months

7825

7683

THY6

Thymus

2413

2266

THY7

0 Months

2341

2290

THY7

Thymus

3430

3171

THY2

0 Months

640

609

THY2

Thymus

1826

1749

Table S2. Table of V(D)J sequence counts and numbers of clones identified from genomic
DNA (gDNA)-based B cell receptor AIRR-Seq.
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Figure S7. Distance-to-nearest plots used to identify a threshold for assigning clonal members
from gDNA-based B cell receptor AIRR-Seq. The graphs (A-C) show the distribution of
junctional distance-to-nearest distances among sequences using the same V gene and J gene
with the same junction length. The minimum between the two modes of this histogram is used
to identify the threshold for assigning clusters of sequences as clones. Upper histograms
within each plot represent within patient nearest-neighbor hamming distances, while lower
histograms within each plot represent between patient distances (which are used to identify the
expected distribution of junctional distance-to-nearest distances for sequences that do not
belong to clones). The dashed vertical red line indicates the threshold used for single linkage
hierarchical clonal clustering.
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Figure S8. Lineage trees displaying two examples of IgG-expressing B cell clones found
in the thymus and circulation before, and 12 months after thymectomy. Tree topologies
and branch lengths were estimated using maximum parsimony. Edge lengths are
quantified based on intervening somatic hypermutations per site between observed V(D)J
sequences per the scale. Tips are colored by antibody isotype, and each internal branch is
colored by whether its descendant node was predicted to have occurred in the thymus or
pre/post thymectomy circulation using a maximum parsimony algorithm (see Methods).
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Figure S9. Amino acid sequence alignments of two representative examples of IgGexpressing B cell clones found in thymus before thymectomy and at 12 months after
thymectomy. The clones (A, B) were both derived from patient THY2. Replacement
mutations are highlighted (blue) relative to the most recent common ancestor (MRCA).
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PATIENT

INCLUDED
CLONES

THYMUS/CIRC.
RATIO

OBSERVED
SP

RANDOM
SP

MEAN 𝛿

P-VALUE

THY1

44

2.7

0.61

0.63

-0.015

0.63

THY2

550

2.4

0.68

069

-0.011

0.83

THY5

2

260

0.8

0.61

0.19

0.27

THY6

80

1.9

0.67

0.61

0.068

0.011

THY7

37

58

0.93

0.87

0.056

0.01

Table S3. Phylogenetic analysis of IgG sequences from thymus and circulation.
“Included clones” indicates the number of clones which contained both thymus and
circulation IgG sequences at the time of thymectomy, and contained more than two
sequences that were either distinct or found in different samples. “Thymus/circ. ratio” is
the ratio of total sequences obtained from the thymus vs. circulation at the date of
thymectomy. “Observed SP” is the proportion of predicted changes that occurred from
the thymus to the circulation in observed lineage trees (detailed in Ref. 60). “Random
SP” is the proportion of predicted changes that occurred from thymus to circulation in
lineage trees with permuted tip locations. “Mean 𝛿” shows the mean difference between
observed and random SP values. The significance of this difference (P value) is the
proportion of 1000 permutation replicates in which 𝛿 ≤ 0. All numbers reported except
“Included Clones” are rounded to two significant digits.
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Figure S10. Correlation of the log fold change in clonal sharing between the thymus and
circulation as assessed with a Bray Curtis index (on the x-axis) and duration of disease
prior to thymectomy in years (y-axis). Correlation is shown for the total repertoire (A) or
the IgG-switched repertoire only (B).
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Abstract
This was a planned analysis of randomized clinical trial to predict myasthenia gravis
symptom control with rituximab (RTX) using measures of clonal B cell persistence
derived from next-generation sequencing of the circulating B cell receptor repertoire.
The B-Cell Targeted Treatment in MG (BeatMG) study was a randomized, double-blind,
placebo-controlled, multicenter phase 2 clinical trial (RCT) that investigated the steroidsparing (primary outcome) and symptom-improving (QMG change, secondary outcome)
effect of rituximab in AChR-Ab+ gMG (generalized myasthenia gravis). Clonal
persistence was quantified in longitudinal peripheral blood mRNA-derived B cell
repertoires relative to baseline at 24 weeks and at the 72-week extension period prior to
unblinding using a Bray-Curtis index. A linear model was used to test for positive
associations between B cell clonal persistence and fractional and absolute change in
QMG score at 52 weeks. A significance threshold of 0.1 was used for exploratory
analysis. 15 participants who received RTX while 14 participants who received placebo
were sequenced; longitudinal QMG data was available for 12 of the RTX-treated
participants after unblinding. A model-corrected positive association was observed
between total and IgG-switched clonal persistence at 24 weeks and fractional change in
QMG score at 52 weeks (P=0.0986, P=0.0481) but not absolute change (P=0.243,
P=0.307). Exploratory analysis showed that RTX reduced B cell clonal persistence of the
total and IgG-switched repertoire relative to placebo at 24 (Wilcoxon-test, P=0.004,
P=0.002 respectively) and 72 (Wilcoxon-test, P=0.014, P=0.033 respectively) weeks.
RTX preferentially depleted IgM B cells (Wilcoxon-test, P=1.7e-6) with lower SHM
(Wilcoxon-test, P=9.5e-7) and spared IgG and IgA-switched B cells (Wilcoxon-test,
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P=0.029 and P=3.41e-4, respectively). An additional negative univariate correlation was
observed between the fractional improvement in QMG and the mean SHM frequency of
persistent IgG-switched B cells (Spearman=-0.590, P=0.072). Thus, a biomarker for the
quality of B cell depletion predicted symptom improvement. These data demonstrate the
importance of B cell depletion quality for the treatment of AChR-Ab+ gMG with
rituximab. This biomarker could serve a valuable role for monitoring depletion in future
investigations on B cell depletion therapy in the context of autoimmunity.

Introduction
Immunotherapy is a mainstay for the treatment of generalized Myasthenia Gravis (gMG).
Multiple retrospective cohort studies have suggested a potential benefit from rituximab
(RTX), a B cell depleting agent.1–5 Consistent with these findings, a multi-center phase 2,
double-blind, placebo-controlled randomized clinical trial was initiated for the use of
RTX in the treatment of AChR-Ab+ gMG patients; however, clinical improvement
compared to placebo was challenging to detect at the conclusion of this trial (manuscript
under review). We hypothesized that variable B cell depletion quality could account for
the lack of any measurable improvement from therapy.

Several studies have identified predictors of poor outcomes from RTX after studying the
frequency of subsets in the circulating B cell compartment; studies characterizing the
circulating B cell compartment after RTX in rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE) have found that the higher frequency of memory B cells and other
antigen-experienced subsets correlate with worse clinical symptom scores after
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treatment.6–12 By studying the B cell repertoire, the persistence of individual B cell clones
can be measured directly to identify biomarker predictors of eventual outcomes. Studies
on rituximab in the treatment of pemphigus vulgaris and motor-neuropathy have shown
an association between clinical responsiveness and clonality, a feature associated with
antigen experienced B cell subsets.13–15 A recent study on ANCA-associated vasculitis
(AAV) demonstrated a direct association between high ANCA-titers and elevated clonal
persistence.16

Given the need for criteria to identify patients who could benefit from additional RTX
and characterize the features of B cells that escape depletion to find targets for future
therapies, the primary goal of this study was to follow the B cell repertoire over time to
understand the basis of heterogeneous outcomes after RTX in AChR-Ab+ gMG. We
investigated both the repertoire as a whole as well as the IgG-switched B cell receptor
repertoire in terms of global features such as isotype distribution, SHM frequency, and
diversity and in terms of clonal overlap and the features of persistent clones. Our findings
suggest that a failure to deplete IgG-switched B cells may play an important role in poor
clinical outcomes and tracing clones using the BCR repertoire could serve as a valuable
biomarker for adequate depletion.

Results
Subject Selection
A total of 52 participants with AChR+ MG were selected for a phase 2 randomized
clinical trial to test the safety and assess the possible efficacy of rituximab. Of these
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participants, 29 were randomly selected for longitudinal BCR repertoire sequencing.
After unblinding, 14 participants were identified to have received the placebo or PCB,
and 15, rituximab or RTX (Table 1). Longitudinal baseline and week 52 QMG data was
available for 14 PCB and 12 RTX treated participants. Of the sequenced participants, the
gender balance (9 male among PCB, 10 male among RTX; 5 female among PCB, 5 male
among RTX) as well as the age distribution (mean of 60.3 years among PCB; mean of
59.4 years among RTX; Wilcoxon test P=0.949) was similar between PCB and RTX.
Two subjects in each arm previously received a thymectomy. The log transformed antiAChR titer was slightly elevated in the PCB group at baseline in 24 weeks (also noted in
main RCT manuscript) (P=0.063, P=070). As expected, the B cell count per volume (per
uL) was significantly lower in the RTX treated group (P=8.5e-6) at 24 weeks.

B cell persistence is a biomarker that predicts relative QMG change
A positive association was detected between Bray-Curtis clonal overlap (between the
baseline and week 24 BCR repertoire) and the absolute change in QMG score, these
differences were not significant (total P=0.243, IgG-switched P=0.307) (Table 2). A
significant association was observed for relative change in QMG score and the total and
IgG-switched Bray Curtis clonal overlap (P=0.0986, P=0.0481 respectively). The model
predicted a 0.01 point increase in total overlap or IgG-switched overlap at week 24 would
be expected to yield a 0.11 or 0.18 point worsening in relative endpoint QMG score. No
other variables in the multivariate linear model used to test for an association were
identified to be significantly associated with relative QMG. Post-hoc exploratory analysis
of other clinical variables and relative QMG change showed no association between the
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log anti-AChR titer at 24 weeks (P=0.686) or the CD19+ CD20+ B cell count by flow
cytometry at 24 weeks (P=0.438) (Table 3).

RTX preferentially depletes isotype-switched B cell subsets, effect not correlated with
relative QMG change

We then sought to explore the effects of RTX on the repertoire and identify possible
additional associations with relative QMG change. Paralleling the decline in B cell count
at 24 weeks, the overall clonal richness at 24 weeks was observed to be significantly
lower in the total (P=9.2e-6) as well as IgG-switched repertoire compared to placebo
(P=1.9e-4; persisting into week 72, P=0.013) (Table 4). IgA and IgG-switched V(D)Js
were observed to represent a disproportionate fraction of the repertoire at 24 weeks
following RTX compared to placebo (P=0.0003, P=0.029) while IgM represented a much
lower fraction (P=1.7e-6, 49.2% vs 7.8%). Moreover, the mean SHM frequency of IgMswitched B cells at 24 weeks was also elevated (P=9.5e-7, 1.4% vs 4.6%) with a trend
observed for IgA-switched sequences as well (P=0.056, 6.8% vs 7.5%). IgG-specific
repertoire metrics were also tested for univariate associations with relative QMG change.
These metrics included total richness, IgG-switched richness, the frequency of IgG
switched V(D)J sequences and the mean SHM frequency of the IgG-switched repertoire
at baseline, 24 and 72 weeks (Table 5). No significant associations were found.

Persistence of IgG-switched B cells with lower SHM associated with worse relative QMG
change
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Additional exploratory analysis was performed examining the association of the
persistent repertoire at 24 weeks and relative QMG change. Bray-curtis overlap at 24
weeks was confirmed to be affected by rituximab treatment and significantly lower in the
RTX-treated group, both overall (P=0.004) and in the IgG-switched repertoire (P=0.002)
(Table 6). These differences also persisted at 72 weeks even as B cell counts recovered
(P=0.014, P=0.033, respectively). No significant differences were observed in terms of
the characteristics of persistent B cell clones between PCB and RTX (those present at
both baseline and 24 weeks) although persistent clones tended to be more IgA-switched
(P=0.065). Persistent IgM clones displayed significantly higher SHM frequency in the
RTX arm (P=0.016).

We then tested an exploratory hypothesis on the effect of RTX on the ability of persistent
B cell clones to reconstitute the repertoire (Table 6). That is, we first tested if RTX
affects whether IgG-switched B cell clones at 24 weeks accumulate SHM by 72 weeks
compared to placebo (quantified in terms of the average log fold SHM change for each
clone between these time points); more SHM accumulation after RTX compared to
placebo was confirmed (P=0.044). We then tested if IgG-switched B cell clones expand
or decrease in size as a fraction of the repertoire between these two time points
differently after RTX; compared to placebo, persistent clones shrink (as a fraction of
repertoire) as B cell counts recover in the RTX arm (P=0.013).
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When associations were examined in comparisons with relative QMG change and the
features of persistent IgG clones, the persistence of IgG-switched clones with lower SHM
frequencies was associated with a worse relative QMG change (P=0.072) (Table 7).

Discussion
Single-center pilot studies have previously demonstrated the benefits of rituximab in
AChR-Ab+ MG as measured by reductions in steroid requirements and symptom score.2,3
However, the randomized phase 2 clinical trial paired with this current study
demonstrated futility, not meeting the pre-defined 30% difference in steroid dose
reduction compared to placebo. While sensitivity analysis from the trial showed
promising trends, including a decreased frequency of exacerbations (12% vs 30%), QMG
score difference (a secondary outcome) was not observed to differ between RTX and
PCB after model correction (-4.0 for RTX vs -1.7 for PCB, p=0.39). Thus, a goal of this
prospectively planned analysis was to identify a mechanistic basis for RCT findings that
could guide the design of future trials.

The secondary outcome of QMG was examined in the main hypothesis of this study in
place of the categorical primary outcome because our proposed biomarker was also
continuous. QMG fold change was preferred over absolute change given its use in a
previous study by our group in which a correlation was identified with B cell clonal
persistence.21 Sensitivity analysis from the trial analysis showed that smaller minimal
point requirements for improvements in QMG score were associated with p-values
approaching significance (a trend not observed for MGC). This basement effect can be
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attributed to the high frequency of patients in this cohort with low baseline QMG scores.
Thus, it was expected that relative QMG difference would provide a more sensitive
measure than absolute QMG. A correction for thymectomy status was included given
previous studies demonstrating an association with poor rituximab outcomes.1 B cell
depletion quality (CD19+, CD20+) was included given extensive studies demonstrating
its use as a predictor in the use of rituximab for other autoimmune disorders.6–8,10,22 Both
the total and IgG-switched repertoire were examined because the IgG-switched repertoire
is strongly implicated in the etiology of AChR MG; known pathogenic antibodies are
IgG-switched.23,24

Tracing B cell clones using NGS-based sequencing successfully predicts disease-free and
overall survival in studies of hematologic malignancies (minimal residual disease).25–31
One previous retrospective study on AAV has also shown an association of B cell clonal
persistence with outcome measures (ANCA titer).16 Likewise, in our study, B cell clonal
persistence was observed to positively associate with relative QMG change when
examining the switched and total BCR repertoire. Thus, our work extend prior findings.

We also demonstrated that rituximab treatment, as compared to placebo, increased both
total and IgG-switched repertoire clonal turnover even as B cell counts returned (at 72
weeks). These associations offer important mechanistic insights and provide evidence
that RTX resets the repertoire. The antigen-experienced clones that return at 72 weeks
were more likely to have a different clonal composition than in subjects treated with
PCB, and the extent of this reset at 24 weeks correlated with relative QMG change. By
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comparison, the absolute count of B cells at 24 weeks was not observed to associate with
relative QMG change, suggesting that following clonal persistence longitudinally may
offer greater predictive utility than individual B cell counts.

Exploratory findings
Exploratory analysis revealed additional insights into the mechanism of RTX in AChR
MG. Different subsets of the repertoire were depleted by RTX which is consistent with
evidence from previous studies on RA and SLE;6,8,10,22,32 where depleted subsets tended
to be CD27- and unswitched by flow cytometry. Our exploratory analysis also parallels a
previous BCR repertoire study on RTX relapse in MuSK MG17 and a similar study on
AAVs.16 Unlike these previous studies, matching placebo samples were also examined
here. Consistent with previous findings, IgA-switched B cells (and IgG-switched to a
more limited extent) and mutated B cells were observed to be preferentially spared when
compared to placebo-treated repertoires.

In contrast to our expectations, the persistence of unmutated IgG-switched B cells rather
than mutated IgG-switched B cells was associated with worse relative QMG change. This
ran counter to our assumption that disease-causing B cells would be more likely to be
antigen-experienced and act as ASCs (which possess higher SHM frequencies).17,33 We
provide two possible explanations for this paradoxical finding: (1) unmutated IgGswitched B cells are associated with active germinal centers, (2) unmutated IgG-switched
B cells are associated with depletion quality. A recent study showed that circulating GC
B cells in the context of flu vaccination that are not related to recall memory B cells have
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lower SHM frequencies, suggesting an origin from naïve B cells.34 The frequency of
germinal centers is a known correlate for higher anti-AChR titers.23,35 Another possibility
states that the association between the persistence of lower SHM B cells and worse QMG
decline after RTX is confounded by the association between greater clonal persistence
and the persistence of lower SHM B cells. That is, the inability to deplete B cells with
lower SHM (which are generally easier to deplete) reflects poor overall depletion
quality.16,17

Limitations
A major potential limitation of this study is that the entire RTX-treated arm of the trial
was not sequenced, reducing statistical power. Our sample size choice reflects a power
calculation that was performed to detect the minimum number of subjects that would
need to be sequenced to answer the primary scientific question of detecting a difference
in persistence/turnover between PCB and RTX; these calculations suggested that only 10
subjects would be needed cohort for 95% power and a level of significance of 0.1. By
sequencing more than 28 subjects we were >95% guaranteed that the RTX and PCB
cohorts would contain >10 patients each. Because we lacked data on the expected
association between overlap and relative QMG score, determining the minimum number
of subjects that would need to be sequenced to identify an association was not possible
and no power calculation was attempted. The identification of a significant association in
the absence of an a priori determination provides post-hoc justification of our sample size
choice. Another limitation of this study was that QMG data was only available for 12 of
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the 15 RTX-treated subjects. Inconsistent collection of clinical outcomes was therefore a
limitation of the RCT.

Summary of future work
A major implication of this study concerns the selection of treatments to trial for AChR
MG. Our finding that the quality of B cell depletion (and not absolute B cell count) is
predictive suggests the depletion of disease-causing B cell subsets in MG may be
improved with agents that target markers other than CD20. This study also confirms our
previous findings that persistent B cell clones tend to be more isotype switched with
higher frequencies of SHM; surface features associated with persistent B cells offer
promising therapeutic targets for future studies.17 This study also provides an important
scientific result by demonstrating that persistent clones do not restore the BCR repertoire
after depletion at 24 weeks. Persistent B cell clones have been identified after RTX
treatment,16,17 but it appears that the frequency of persistent B cell clones is far lower
after RTX compared to PCB. At least some B cell clones present after RTX arise de
novo—more B cell clones arising de novo is associated with better outcomes. Finally,
these results demonstrate that B cell clonal overlap could provide a metric for titering the
dose of RTX and could therefore serve as an important biomarker for clinical decision
making.

Methods
Study Design

139

Participants in this study were part of a multicenter, randomized, double-blind, placebocontrolled phase 2 trial (BeatMG, NCT02110706) with a primary outcome of futility:
<30% difference in terms of significant steroid reduction (>75%) between placebo and
rituximab arms at week 52. A secondary primary outcome of safety was also assessed for
differences in adverse and serious adverse event frequency. Inclusion criteria included
patients with MGFA II-IV AChR-Ab+ gMG between the ages of 21 and 90 enrolled from
2014 to 2016 involving 16 NeuroNEXT (Network for Excellence in Neuroscience
Clinical Trials, organized by NINDS)-sponsored centers. Exclusion criteria included
thymectomy in the previous 6 months, previous RTX or natalizumab treatment or
previous IVIg/PLEX within 4 weeks. Stable prednisone or immunosuppressive therapy
(azathioprine, tacrolimus, cyclosporine, mycophenolate, methotrexate) was permitted in
the previous 4 weeks. Anti-AChR antibody levels were measured by Mayo Medical
Laboratories and log scaled for our investigations (range, >0.02 nM). B cell counts
(CD20+ CD19+) were quantified by flow cytometry to monitor for depletion by the
University of Rochester Laboratory (range, 120-725 cells/uL). Patients received two
cycles of rituximab with the first administered at weeks 0-3 and the second at weeks 2427; the placebo treatment contained only vehicle. Prednisone tapering was determined
based on MGC score according to a protocol detailed in the statistical analysis plan.

Repertoire Sequencing
Peripheral blood mononuclear cells were isolated from whole blood and frozen in liquid
nitrogen for storage. Samples were thawed in a 37 C bath followed by flow cytometry
(see Supplemental Methods 1 for antibody panel and protocol) and immediate lysis buffer
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addition. RNA was prepared using the Qiagen RNEasy Mini kit per manufacturer's
instructions (Cat. 74104). Bulk IGH libraries were prepared using the NEBNext Immune
Sequencing Kit from New England Biolabs as described previously.17

In brief, preparation of these libraries first involved the use a template-switch reverse
transcriptase to add a 17 nucleotide unique molecular identifier to the 5' end of each
cDNA molecule which was subsequently amplified to enrich for IGH (including
IGHA/E/D/M/G) and TCRB V(D)J sequences using 3'-specific primers. Two rounds of
PCR were used that added a 5' specific index primer and Illumina P5 adaptor sequences
to each amplicon. Libraries were pooled and sequenced by paired-end sequencing with
325 cycles for read 1 and 275 cycles for read 2 on the Illumina MiSeq platform per
manufacturer's instructions. A 20% PhiX spike-in was used.

Reconstruction of sequenced libraries was performed using the Immcantation framework
(immcantation.org). Preprocessing was first performed using pRESTO v0.5.10.49 as
described previously.17,18 Re-assembled V(D)J sequences were then assigned to a
germline V(D)J gene reference using IgBLAST v1.14.0 using the December 1, 2019
IMGT gene database.19 Constant region isotypes were assigned by aligning a set of
internal sequences associated with different isotype classes to the 3' sequence of the
reconstructed V(D)J sequence; a match with one of these sequences was sufficient for
assignment. Heavy chain sequences identified based on VH and JH gene assignments
were included and non-functional sequences were removed.
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Clonal groups were assigned using Change-O v0.3.4 as defined previously.20 Sequences
were first partitioned based on common IGHV and IGHJ genes and common junction
lengths; clusters of sequences with junction sequences that differed by less than a length
normalized Hamming distance threshold were then grouped into clones by single linkage
clustering. A threshold was identified to cut the tree based on the local minima of the two
modes of a within subject distance-to-nearest histogram (see Supplemental Figure 1)
using a kernel density estimate for each subject; thresholds for clonal assignment for each
subject are provided in the supplemental (see Supplemental Table 1). Germline V(D)J
sequences were then reconstructed for each clonal cluster with D gene and N/P region
masking. The somatic hypermutation frequency of each V(D)J sequence was computed
for the VH gene region relative to the reconstructed V(D)J sequence using SHazaM
v0.1.8 in R. Sharing of clones across time points was computed using a Bray-Curtis
metric implemented using the scipy (v1.1.10) function scipy.spatial.distance.braycurtis.
For T cells, clones were identified based on sharing of the same full length aligned V(D)J
nucleotide sequence.

Statistical Analysis
The primary hypothesis was assessed by fitting the following linear model: 𝑌! = 𝛽" +
𝛽# 𝑋$%&'()*+'&,! + 𝛽- 𝑋./+0,! + 𝛽1 𝑋23(4/56,! . In this model, 𝑌! represents QMG score
change for the ith subject; 𝑋$%&'()*+'&,! indicates whether the ith subject previously
received thymectomy; 𝑋./+0,! is the B cell count per uL for the ith subject at 24 weeks;
𝑋23(4/56,! is the Bray-Curtis clonal overlap at 24 weeks with baseline. The following onesided hypothesis was then tested after model correction: 𝐻" : 𝛽1 > 0 𝑣𝑠. 𝐻7 : 𝛽1 ≤ 0. The
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glm function in base R was used to fit the model. Given the one-sided nature of the
hypothesis, p-values reported for the overlap coefficient (which were positive) were
divided by 2. Exploratory analyses were conducted investigating differences between
rituximab and placebo were computed using unpaired, two-tailed, Wilcoxon tests.
Exploratory analyses of associations between log anti-AChR titer, B cell counts or
repertoire metrics were conducted using one-tailed or two-tailed Spearman correlation
coefficients (specified in Tables). No imputation was performed in this study. Analysis
for correlation with repertoire metrics was omitted for participants without paired QMG
data. Similarly, univariate testing for differences between rituximab and placebo were not
computed if metrics were not available (specified for each table). A significance
threshold of 0.1 was used for all statistical testing as defined in the statistical analysis
plan and for consistency with the paired trial which used the same threshold.

Sample Size Justification
The sample size for investigating a repertoire-based biomarker was based on the sample
depth necessary to detect differences between placebo and rituximab in terms of clonal
overlap. In a previous study on relapses after RTX in patients with MuSK MG, an
average clonal overlap of 0.025 was identified, with a range from 0.015 to 0.035 (a
standard deviation of 0.01).17 It should be noted that the period of time spanned in this
previous study was longer than that examined here with a lower bound of approximately
one year. We assumed that the placebo overlap at 24 weeks would average at the upper
end of the distribution at 0.035. Assuming a gaussian error distribution and the same
standard deviation, 95% power could be achieved with a sample size of ten for each
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group to detect a difference in clonal overlap of 0.025. Because RTX and PCB
assignments were blinded at the time of sequencing, we used a binomial distribution to
calculate that sequencing 28 of the 50 samples (assuming an expected 50/50 distribution
of rituximab and placebo) would guarantee a >95% likelihood of sequencing >10
rituximab subjects. Further details are provided in the statistical analysis plan.
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Tables
Placebo

Rituximab

BCR Sequenced Total

14

15

BCR Sequenced with QMG data

14

12

Male

9

10

Female

5

5

60.3(13.9)

59.4(16.6)

2

2

Log AChR titer at Baseline

-0.03(1.58)

1.56(2.21)

0.063

Log AChR titer at 24 weeks

0.10(1.58)

1.34(1.87)

0.070

123.4(123.3)

3.0(4.3)

8.49E-06

Age
Previous Thymectomy

Clinical B cell count at 24 weeks (per uL)

P-value

0.949

Table 1. Table of demographic characteristics of cohort selected for BCR sequencing.
Standard deviations enclosed in parentheses. P-values correspond to two-tailed Wilcoxon
tests with a significance threshold of 0.10.
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Isotype

QMG Change

Estimate

P-value

IgG

Absolute

87.34

0.3072

IgG

Relative

17.51

0.0481

Total

Absolute

99.64

0.2432

Total

Relative

11.18

0.0986

Table 2. Planned analysis test of biomarker association hypothesis (n=12 participants for
all tests of association) quantifying significance using a linear model. Estimates
correspond to the value of the coefficient paired with the overlap metric.
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Log AChR titer at 24 weeks
Clinical B cell count at 24 weeks

P-value
0.686
0.438

Spearman Rho
-0.130
0.050

Tested direction if one-sided
Positive

Table 3. Exploratory univariate test of association between available clinical biomarkers
from central laboratory and relative QMG change among subjects selected for BCR
sequencing (n=12 participants for tests of association).
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Placebo

Rituximab

P-value

60.6(0.6)*

60.2(1.1)

0.489

Richness at 24 weeks

60.8(0.2)

55.6(5.4)**

9.23E-06

Richness at 72 weeks

60.8(0.2)

57.4(6.9)***

0.284

12.87(0.15)*

12.75(0.35)

0.532

IgG Richness at 24 weeks

12.90(0.08)

11.91(1.29)**

1.91E-04

IgG Richness at 72 weeks

12.92(0.05)

12.09(1.85)***

0.013

IgA Frequency at baseline

0.237(0.090)*

0.286(0.141)

0.339

IgA Frequency at 24 weeks

0.277(0.110)

0.560(0.218)

3.41E-04

IgA Frequency at 72 weeks

0.272(0.149)

0.371(0.247)***

0.454

IgG Frequency at baseline

0.225(0.137)*

0.228(0.138)

1.000

IgG Frequency at 24 weeks

0.231(0.148)

0.362(0.218)

0.029

IgG Frequency at 72 weeks

0.221(0.162)

0.221(0.180)***

0.946

IgM Frequency at baseline

0.537(0.201)*

0.486(0.248)

0.525

IgM Frequency at 24 weeks

0.492(0.233)

0.078(0.071)

1.73E-06

IgM Frequency at 72 weeks

0.507(0.282)

0.408(0.366)***

0.454

IgA Mean SHM at baseline

0.068(0.008)*

0.066(0.008)

0.363

IgA Mean SHM at 24 weeks

0.068(0.007)

0.075(0.009)**

0.056

IgA Mean SHM at 72 weeks

0.067(0.007)

0.069(0.006)***

0.635

IgG Mean SHM at baseline

0.069(0.010)*

0.066(0.006)

0.618

IgG Mean SHM at 24 weeks

0.069(0.009)

0.074(0.012)

0.400

IgG Mean SHM at 72 weeks

0.068(0.010)

0.071(0.013)***

0.734

IgM Mean SHM at baseline

0.014(0.007)*

0.017(0.008)

0.294

IgM Mean SHM at 24 weeks

0.014(0.009)

0.046(0.016)**

9.47E-07

IgM Mean SHM at 72 weeks

0.015(0.013)

0.024(0.026)***

0.793

Richness at baseline

IgG Richness at baseline

Table 4. Exploratory univariate testing of changes to the repertoire caused by RTX in
comparison to placebo. (n=14 vs. n=15).
*In this comparison, the baseline sample for subject 122-1052 was not collected and
omitted.
**In this comparison, only 2 non-persistent IgG sequences were isolated from subject
122-1050 at 24 weeks, not sufficient to compute diversity and quantify IgM and IgA
statistics.
***In this comparison, the 72 week sample for subject 185-1055 was not collected and
omitted.
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P-value

Spearman Rho

Tested direction if one-sided

Richness at baseline

0.570

0.183

Richness at 24 weeks*

0.232

-0.393

Richness at 72 weeks**

0.553

0.201

IgG Richness at baseline

0.570

0.182

IgG Richness at 24 weeks*

0.256

-0.375

IgG Richness at 72 weeks**

0.609

0.174

IgG Frequency at baseline

0.664

-0.136

Positive

IgG Frequency at 24 weeks*

0.858

-0.337

Positive

IgG Frequency at 72 weeks**

0.916

-0.447

Positive

IgG Mean SHM at baseline

0.997

0.001

IgG Mean SHM at 24 weeks*

0.970

-0.012

IgG Mean SHM at 72 weeks**

0.104

-0.517

Table 5. Exploratory univariate testing of IgG associated features and relative QMG
change. n=12 for all comparisons except those annotated.
* In this comparison, only IgG sequences were isolated from subject 122-1050 at 24
weeks, not sufficient to compute diversity and quantify IgM and IgA statistics.
** In this comparison, the 72 week sample for subject 185-1055 was not collected and
omitted.
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Placebo*

Rituximab

P-value

Overlap at 24 weeks
Overlap at 72 weeks

0.035(0.020)
0.025(0.014)

0.017(0.028)
0.018(0.035)**

0.004
0.014

IgG Overlap at 24 weeks
IgG Overlap at 72 weeks

0.049(0.028)
0.035(0.019)

0.013(0.022)
0.020(0.028)**

0.002
0.033

Persistent IgA Frequency 24 weeks

0.355(0.190)

0.065

Persistent IgG Frequency 24 weeks
Persistent IgM Frequency 24 weeks

0.333(0.243)
0.312(0.261)

0.516(0.279)†
0.255(0.198)†

Persistent IgA Mean SHM 24 weeks

0.229(0.334)†

0.452
0.132

0.074(0.018)

0.076(0.012)†

0.852

Persistent IgG Mean SHM 24 weeks

0.312(0.261)

0.132

Persistent IgM Mean SHM 24 weeks

0.039(0.013)

0.229(0.334)†
0.052(0.016)†

IgG SHM accumulation from 24 to 72 weeks
IgG Clone expansion from 24 to 72 weeks

0.006(0.013)
0.101(0.636)

0.090(0.150)†

0.044
0.013

-0.472(1.003)†

0.016

Table 6. Exploratory univariate testing of changes to the persistent repertoire caused by
RTX in comparison to placebo. Persistent frequencies and SHM frequencies are
computed for the subset of persistent V(D)J sequences; samples without persistence
V(D)J sequences were therefore not included in this analysis. Overlap was quantified
using a Bray-Curtis index.
* In these comparisons, the baseline sample for subject 122-1052 was not collected and
omitted.
** In this comparison, the 72 week sample for subject 185-1055 was not collected and
omitted.
†In this comparison, only IgG sequences were isolated from subject 122-1050 at 24
weeks, none of which were persistent.
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P-value

Spearman Rho

Tested direction if onesided

IgG Frequency in 24 week overlap*

0.807

-0.290

Positive

IgG Mean SHM in 24 week overlap**
IgG SHM accumulation 24 to 72
weeks†

0.072

-0.590

0.405

-0.317

IgG clone expansion 24 to 72 weeks†

0.565

-0.222

Table 7. Exploratory univariate testing of persistent IgG associated features and relative
QMG change.
*n=11 subjects were involved in this comparison as no persistent V(D)J sequences were
identified for subject 122-1050 at week 24.
**n=10 subjects were involved in this comparison as no persistent IgG sequences were
identified for subject 122-1050 and 108-1028 at week 24.
†n=9 subjects were involved in this comparison as no persistent IgG sequences were
identified for subject 122-1050 and 108-1028 at week 24; also, the 72 week sample for
185-1055 was never collected and therefore omitted.
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Chapter 5: Concluding Remarks
Main thesis
In this thesis, I present evidence that B cell persistence mediates poor responses to
therapies targeting disease-associated B cell subsets in autoimmunity. I illustrate these
findings in the context of MG, an autoimmune disease caused by antigen-specific B cells.

We present two non-mutually exclusive explanations for why such a relationship could
exist. (Chapter 2) We first show that B cell clones that are specific for autoantigen and
capable of producing autoantibodies may re-emerge after depletion. This suggests that the
escape of antigen-specific B cell clones may cause disease persistence. (Chapter 3) We
then show that outcomes –after the removal of a tissue source (by surgery) known to
contain antigen-specific B cell subsets – are improved when fewer clones related to that
structure persist afterwards in the circulation. This raises the possibility that the poor
depletion of B cells from a tissue reservoir may cause disease persistence in MG.

Thus, poor responses to B cell depletion therapy may arise from the failure to deplete
individual disease-associated clones with these two characteristics—those that are
specific for antigen and those that are tissue-localized. In the context of systemic B cell
depletion, poor quality B cell depletion/turnover from treatment would directly increase
the likelihood that these individual disease-associated clones persist. We tested this
hypothesis in a set of planned analyses on randomized clinical trial samples for the use of
rituximab in MG (Chapter 4). These findings help guide new clinical trials on diagnostic
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and therapeutic options in MG and present impactful new scientific questions to
investigate.

Translating findings into useable diagnostics
A major implication of this thesis research concerns the development new diagnostic
tools for monitoring and predicting treatment responses in MG by following B cell clones
over time. Previous work on the use of BCR tracing for the monitoring of treatment for
hematologic malignancy provide examples of how this thesis research could be
translated.

In the field of hematologic malignancies, the term minimal residual disease (MRD) is
used to describe the monoclonal or oligoclonal persistence of malignant cells; MRD is
defined formally as the presence of residual malignant cells in the absence of clinical
disease. Extensive studies in ALL have demonstrated the value of DNA and RNA based
bulk NGS AIRR-Seq for MRD (187–189) showing greater accuracy than flow cytometry
for prognosis (177, 190). MRD detection by AIRR-Seq has also been shown to more
accurately predict relapses after treatment (178, 179, 191) and allow for more less
invasive monitoring through the use of peripheral blood rather than. bone marrow (179,
192). Studies in CLL (180, 181, 193) and MM (182, 183, 194) have replicated these
findings in classifying patients based on disease-free survival (DFS) outcomes and have
shown utility for MRD detection in treatment planning. Another study demonstrated that,
like ALL, peripheral blood could provide a less invasive way of monitoring MRD in MM
(195). Collectively, this work shows the steps necessary for bulk AIRR-Seq to become
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widely used as an acceptable modality for monitoring B cell depletion. Multiple
prospective studies across a large patient cohort with consistent outcome measure are
needed to show the generalizability of the findings presented here.

In contrast to B and T cell lymphocytic malignancies, the role of monoclonal or
oligoclonal expansions had not yet been rigorously established in the context of
autoimmunity prior to this thesis research. No evidence of stable clonal expansions in
MG were found in earlier work (99). This lack of evidence, however, does not preclude
the possibility that B cell persistence could be associated with worse outcomes in the
context of B cell depletion. Several studies have provided evidence of this possibility
(46–48, 54, 75, 76). Given the promise of AIRR-Seq in monitoring hematologic
malignancy outcomes, the identification of similar MRD-like biomarkers for monitoring
outcomes in autoimmune disease motivated our studies. Prior to this thesis work, only
one other study had identified a significant clinical association for oligoclonal B cell
persistence (48). In this study, increased clonal overlap (quantified as the ratio of
persistent clonal BCRs over the number of total BCRs—similar to the Bray-Curtis metric
we use) was observed to be associated with higher ANCA titers in patients with ANCAassociated autoimmune vasculitis (48). ANCA titers are known to correlate well with
disease outcomes so while this study did not establish associations with outcome, the
results parallel those presented here (except its retrospective nature) (196, 197). Our work
as well as the work from this study demonstrate the possible generalizability of AIRRSeq as a way to monitor BCDT treatments for autoimmune disease.
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Alternative therapeutics that should be investigated
This thesis research also has implications on future directions in the improvement of B
cell depletion agents for the treatment of MG. B cell depletion therapy with anti-CD20
monoclonal antibodies is currently part of the treatment for MuSK MG and is
investigational for the treatment of AChR MG. Historically, this was first motivated by a
case report describing a patient with AChR MG whose symptoms improved after
treatment with RTX (for malignancy) (198). Other groups subsequently investigated
RTX in AChR and MuSK MG retrospectively with considerable success (5, 6, 8); these
studies demonstrated 100% complete stable remission (CSR) for the use of RTX in
MuSK MG. However, subsequent studies reported that some patients with AChR MG
relapsed at a frequency of 54-56% (4, 175). Consequently, a major goal of this thesis
research involved identifying alternative methods of B cell depletion that could more
precisely target disease-causing subsets and prevent relapse. These therapies would be
particularly relevant to investigate in new clinical trials.

The depletion of plasma cells for the treatment of AChR MG is briefly discussed in
Chapter 3 of this thesis; we detail possible strategies for targeting this B cell subset here.
CD19 is a surface marker that is expressed before the expression of CD20 in pro-B cells
and declines after the expression of CD20 in plasma cells. CD19+ plasma cells are more
abundant than CD20+ plasma cells; targeting CD19+ cells expands the range of B cell
subsets ablated by depletion therapy (199). MEDI-155 or inebilizumab is an IgG
monoclonal that binds CD19 and targets B cells for depletion. Inebilizumab was
demonstrated to be more effective than anti-CD20 depletion in EAE, a mouse model of
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multiple sclerosis (200, 201) owing to the enhanced depletion of plasma cells in the bone
marrow according to authors. Two phase 1 trials for its use in relapsing-remitting
multiple sclerosis (202) and systemic sclerosis (203) reported promising findings. A
phase 2/3 trial initiated for its use in the treatment of NMO have also been successful
(169). Thus, anti-CD19 should also be one of the first agents to explore for the treatment
of MG (such as in the ongoing MINT trial) given indications on the importance of plasma
cells and CD20low B cells in poor therapy responses shown by this thesis research.

Given the potential contribution of long-lived plasma cells to the production of diseasecausing autoantibodies in AChR MG, direct plasma cell activity with proteasome
inhibitors have also shown promise. Bortezomib is a proteasome inhibitor demonstrated
to have phase 2 efficacy in the treatment of autoimmune hematologic disease such as
(AIHA, ITP and TTP) (204). CD138+ IgG+ populations from AChR MG thymocytes are
necessary for the production of anti-AChR antibodies and bortezomib may be to be
sufficient for targeting these subsets (25). Studies on plasma cells from AChR MG
thymus have also been replicated with other proteasome inhibitors such as ONX-0914
(205). A phase 2 trial called TAVAB for bortezomib in generalized AChR MG (but also
SLE, RA) was recently initiated with a primary endpoint of AChR autoantibody titer
decrease (206).

Another therapeutic target of considerable interest in MG is the BAFF/APRIL axis as
described in Chapter 2 of this thesis. BAFF and APRIL are B cell stimulatory molecules
that promote B cell proliferation and B cell survival, somatic hypermutation as well as
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autoimmunity (based on numerous studies of rodent-based models of human
autoimmunity) (207). The anti-BAFF therapy belimumab was approved by the FDA for
the treatment of SLE after demonstrating efficacy in a phase 3 RCT (208). Elevated
BAFF levels have also been observed in patients with AChR MG and MuSK MG, and
BAFF levels are known to correlate with higher autoantibody titer (209–211). The
thymus has also been observed to be enriched in BAFF-producing myeloid populations
(212, 213). However, results from a recent RCT on the use of belimumab in AChR MG
failed to meet the primary endpoint of a change in QMG score (214).

BAFF has also been shown to correlate with poor responses to RTX in RA and Sjogren's
disease raising the possibility that combination therapy with B cell depleting agents may
be viable (59–61). The BAFF receptor antagonist atacicept (a fusion protein that blocks
both APRIL and BAFF) was recently trialed (phase 2) for the treatment of SLE with
promising results (215). However, it was also shown to exacerbate disease activity in
patients with relapsing MS in a trial setting (216). Thus, while targeting the
BAFF/APRIL axis may be another avenue to pursue for the treatment of MG, further
studies are necessary to understand how the B cell subsets targeted by these agents differ
from those targeted by CD20 and the implications that depleting these subsets may have
on disease.

Basic science implications and ideas for future research
The data in this thesis provide compelling evidence that the persistence of antigenexperienced B cell clones specific for autoantigen derived from tissue sources may

157

mediate poor outcomes in MG. While this supports our main hypothesis for why BCDT
may fail in some patients, these findings do not exclude alternative hypotheses for how
autoantibodies could arise during poor responses to RTX. One major alternative
hypothesis concerning the origin of autoantigen-specific B cells after RTX is that
autoantigen-specific clones continuously emerge de novo from the naive repertoire. This
hypothesis also has particularly interesting theoretical implications on our understanding
of immunological memory.

Several lines of evidence appear to support this possibility. The foreign or self-reactivity
profile of the naive repertoire is known to be highly consistent within individuals (217–
219). Differences in the autoreactivity of the naive repertoire observed in the context of
other autoimmune disorders have also been observed for MG (167, 220, 221). This is
reflected in the VH gene distribution of the naive repertoire which is different in MG
compared to healthy repertoires (99). Moreover the naive VH gene profile is known to be
highly consistent within subjects and highly dependent on genetic background (or the
resident microbiome (222, 223)) rather than environmental exposure (224–226). Thus, B
cell depletion would not be expected to significantly affect the specificity profile of the
naive B cell compartment for self, a hypothesis confirmed in a study of tolerance check
point defects in type I diabetes (227).

Nevertheless, the existence of a permanent autoreactive naive background in patients
with MG does not directly prove that anti-AChR and MuSK naïve B cells continuously
supply the antigen-experienced repertoire. The VH gene repertoire of the antigen-
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experienced (“non-naïve”) compartment appears to be driven less by genetic background
compared to the naive compartment (224, 226). Differences in the autoreactivity of the
isotype-switched compartment have not been consistently observed for individuals
diagnosed with autoimmunity compared to healthy controls (221, 228). Moreover, SHM
has consistently been shown to reduce germline BCR autoreactivity and promote
reactivity against non-self (229, 230). Genome-wide association studies for autoimmune
diseases implicate similar genes across different categories of autoimmune disease (231)
with similar findings for MG (232); while MG patients may be broadly predisposed to
developing autoimmune disease, no evidence currently suggests any specific genetic
predisposition for MG versus another autoimmune disorder (232, 233).

We never directly addressed this hypothesis concerning naïve B cells in our
investigations as it was not mutually exclusive to the hypothesis we sought to test
regarding the antigen-experienced compartment. In exploratory analyses, we did not
observe any correlates between the VH gene usage of the naive repertoire and outcomes
after RTX in MG; how well the naive repertoire was able to restore its VH gene
repertoire never correlated with whether the patient responded well to RTX.

Nevertheless, a more rigorous treatment is merited for these investigations. This
hypothesis should also be investigated from an alternative perspective: is it possible that
convergent evolution can regenerate an antigen-experienced clone specific for
autoantigen from a naive B cell precursor, perhaps driven only by T cell memory?
Tantalizing evidence suggests that given enough time and stimulation, this could occur.
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In a mouse model of chronic OVA stimulation with a transgenic BCR (against
hemagglutinin), continual immunization was observed to lead to the production of OVAspecific antibodies over the course of months—driven by T cell driven selection of B
cells undergoing SHM (234). Persistent T cell clones in MG could similarly select for
convergent evolution toward autoantigen specificity among naive B cells given enough
time and exposure to autoantigen. In our own analysis, we did not observe any
correlations between outcomes, TCR diversity and B cell persistence in our study,
however our analyses were exploratory and pooled different T cell subsets like CD4 T
cells, Tregs, and CD8 T cells, increasing noise.

While the hypothesis that T cell memory driving convergent evolution in B cells would
be interesting to test, a rigorous examination of this hypothesis in humans would be
difficult. This is because of the difficulty of studying B cell convergent evolution in
general—we would need a precise enough model of the B cell repertoire in the absence
of selection to detect greater convergence than expected by chance or technical error.
Nevertheless, while we show that the persistence of specific antigen-experienced B cell
clones causes poor outcomes after RTX, we do not rule out the possibility that B and T
cell crosstalk could also contribute to the re-generation of these clones from naive
sources. Moreover, these fundamental questions about the sources of immunological
memory are worth pursuing especially if we are to learn how to better promote
immunological memory that is beneficial while keeping those that are detrimental at bay.
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